<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Enzyme Inhib Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Enzyme Inhib Med Chem</journal-id><journal-title-group><journal-title>Journal of Enzyme Inhibition and Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">1475-6366</issn><issn pub-type="epub">1475-6374</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7901698</article-id><article-id pub-id-type="pmid">33615947</article-id><article-id pub-id-type="doi">10.1080/14756366.2021.1882453</article-id><article-id pub-id-type="publisher-id">1882453</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Reconsidering anion inhibitors in the general context of drug design studies of modulators of activity of the classical enzyme carbonic anhydrase</article-title><alt-title alt-title-type="left-running-head">A. Nocentini et al.</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3342-702X</contrib-id><name><surname>Nocentini</surname><given-names>Alessio</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1470-7192</contrib-id><name><surname>Angeli</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Carta</surname><given-names>Fabrizio</given-names></name><xref ref-type="aff" rid="AF0001">a</xref></contrib><contrib contrib-type="author"><name><surname>Winum</surname><given-names>Jean-Yves</given-names></name><xref ref-type="aff" rid="AF0002">b</xref></contrib><contrib contrib-type="author"><name><surname>Zalubovskis</surname><given-names>Raivis</given-names></name><xref ref-type="aff" rid="AF0003">c</xref><xref ref-type="aff" rid="AF0004">d</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8698-9440</contrib-id><name><surname>Carradori</surname><given-names>Simone</given-names></name><xref ref-type="aff" rid="AF0005">e</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3314-2411</contrib-id><name><surname>Capasso</surname><given-names>Clemente</given-names></name><xref ref-type="aff" rid="AF0006">f</xref></contrib><contrib contrib-type="author"><name><surname>Donald</surname><given-names>William A.</given-names></name><xref ref-type="aff" rid="AF0007">g</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4262-0323</contrib-id><name><surname>Supuran</surname><given-names>Claudiu T.</given-names></name><xref ref-type="aff" rid="AF0001">a</xref><xref ref-type="corresp" rid="AN0001"/></contrib><aff id="AF0001"><label>a</label><institution>Neurofarba Department, Pharmaceutical and Nutraceutical Section, University of Florence</institution>, <city>Florence</city>, <country>Italy</country></aff><aff id="AF0002"><label>b</label><institution>IBMM, Univ. Montpellier, CNRS, ENSCM</institution>, <city>Montpellier</city>, <country>France</country></aff><aff id="AF0003"><label>c</label><institution>Latvian Institute of Organic Synthesis</institution>, <city>Riga</city>, <country>Latvia</country></aff><aff id="AF0004"><label>d</label><institution>Institute of Technology of Organic Chemistry, Faculty of Materials Science and Applied Chemistry, Riga Technical University</institution>, <city>Riga</city>, <country>Latvia</country></aff><aff id="AF0005"><label>e</label><institution>Department of Pharmacy, "G. d'Annunzio" University of Chieti-Pescara</institution>, <city>Chieti</city>, <country>Italy</country></aff><aff id="AF0006"><label>f</label><institution>Institute of Biosciences and Bioresources, National Research Council</institution>, <city>Napoli</city>, <country>Italy</country></aff><aff id="AF0007"><label>g</label><institution>School of Chemistry, University of New South Wales</institution>, <city>Sydney</city>, <country>Australia</country></aff></contrib-group><author-notes><corresp id="AN0001"><bold>CONTACT</bold> Claudiu T. Supuran <email>claudiu.supuran@unifi.it</email><institution>Neurofarba Department, Pharmaceutical and Nutraceutical Section, University of Florence</institution>, <addr-line>Via Ugo Schiff 6, Sesto Fiorentino</addr-line>, <city>Florence</city>, <postal-code>50019</postal-code>, <country>Italy</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>21</day><month>2</month><year>2021</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2021</year></pub-date><volume>36</volume><issue>1</issue><fpage seq="54">561</fpage><lpage>580</lpage><permissions><copyright-statement>&#x000a9; 2021 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IENZ_36_1882453.pdf"/><abstract><title>Abstract</title><p>Inorganic anions inhibit the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) generally by coordinating to the active site metal ion. Cyanate was reported as a non-coordinating CA inhibitor but those erroneous results were subsequently corrected by another group. We review the anion CA inhibitors (CAIs) in the more general context of drug design studies and the discovery of a large number of inhibitor classes and inhibition mechanisms, including zinc binders (sulphonamides and isosteres, dithiocabamates and isosteres, thiols, selenols, benzoxaboroles, ninhydrins, etc.); inhibitors anchoring to the zinc-coordinated water molecule (phenols, polyamines, sulfocoumarins, thioxocoumarins, catechols); CAIs occluding the entrance to the active site (coumarins and derivatives, lacosamide), as well as compounds that bind outside the active site. All these new chemotypes integrated with a general procedure for obtaining isoform-selective compounds (the tail approach) has resulted, through the guidance of rigorous X-ray crystallography experiments, in the development of highly selective CAIs for all human CA isoforms with many pharmacological applications.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>carbonic anhydrase</kwd><kwd>inhibitor</kwd><kwd>sulphonamide</kwd><kwd>inhibition mechanisms</kwd><kwd>cyanate</kwd></kwd-group><counts><fig-count count="9"/><table-count count="0"/><page-count count="20"/><word-count count="17893"/></counts></article-meta></front><body><sec sec-type="intro" id="S0001" disp-level="1"><label>1.</label><title>Introduction</title><p>Carbonic anhydrase (CA, EC 4.2.1.1) was discovered almost a century ago by Meldrum and Roughton<xref rid="CIT0001" ref-type="bibr"><sup>1</sup></xref> who described its efficient catalysis for the reversible hydration of blood CO<sub>2</sub> to bicarbonate and protons. Subsequently, such a process was shown to be relevant physiologically for many systems in organisms throughout the phylogenetic tree<xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="CIT0003" ref-type="bibr"><sup>3</sup></xref>. Relevant discoveries on the catalytic and inhibition mechanisms of this enzyme were thereafter mainly done by a Swedish scientist, in the period from the 60&#x02009;s to the 80&#x02009;s, S. Lindskog, who proposed the catalytic mechanism that is still valid today<xref rid="CIT0004" ref-type="bibr"><sup>4</sup></xref>, i.e. the enzyme contains a nucleophilic zinc hydroxide species that can hydrate CO<sub>2</sub> in a two-step, &#x0201c;ping-pong&#x0201d; process, as follows: (i) the attack of CO<sub>2</sub> by the zinc hydroxide bound within the active site of the enzyme resulting in formation of bicarbonate, which is released into solution, and (ii) regeneration of the zinc hydroxide nucleophilic species by a proton transfer reaction from a zinc-coordinated water molecule to the reaction medium, which is the rate-determining step of the catalytic cycle<xref rid="CIT0004" ref-type="bibr"><sup>4</sup></xref>. The first investigation of anion CA inhibitors (CAIs) were also performed by Lindskog on both native and cobalt(II)-substituted enzymes<xref rid="CIT0005" ref-type="bibr"><sup>5</sup></xref>, demonstrating by means of electronic spectroscopic techniques (using the cobalt-enzyme) that such inhibitors coordinate to the catalytic metal ion in a tetrahedral or trigonal-bipyramidal geometry<xref rid="CIT0003" ref-type="bibr"><sup>3&#x02013;5</sup></xref>. The first crystallographic studies of a CA isoform were also reported by researchers from Sweden (Lindskog&#x02019;s and Nyman&#x02019;s groups)<xref rid="CIT0006" ref-type="bibr"><sup>6</sup></xref>, whereas the first complete structure, that of human (h) isoform hCA II was published in 1972<xref rid="CIT0007" ref-type="bibr"><sup>7</sup></xref>.</p><p>Sulphonamides were reported to be CAIs in 1940 by Mann and Keilin<xref rid="CIT0008" ref-type="bibr"><sup>8</sup></xref> who also reported some side effects that were observed with the newly discovered (in 1940) antibacterial drug sulphanilamide (4-amino-benzenesulfonamide). Krebs on the other hand published the first comprehensive structure-activity relationship (SAR) study of sulphonamide inhibitors<xref rid="CIT0009" ref-type="bibr"><sup>9</sup></xref> and together with Roughton, one of the co-discoverers of the enzyme, proposed CA as &#x0201c;a tool in studying the mechanism of reactions involving H<sub>2</sub>CO<sub>3</sub>, CO<sub>2</sub> or HCO<sub>3</sub><sup>&#x02212;</sup>&#x0201d;<xref rid="CIT0010" ref-type="bibr"><sup>10</sup></xref>, which is role that these enzymes still have today after thousands of valuable studies that have been performed worldwide<xref rid="CIT0011" ref-type="bibr"><sup>11&#x02013;15</sup></xref>. This is probably due primarily to the fact that CAs are drug targets for a multitude of disorders, which are aspects that will be discussed later in this review.</p><p>Nowadays, eight CA genetic families are known in organisms from across the phylogenetic tree, more precisely &#x003b1;-, &#x003b2;-, &#x003b3;-, &#x003b4;-, &#x003b6;-, &#x003b7;-, &#x003b8;- and &#x003b9;-CAs<xref rid="CIT0016" ref-type="bibr"><sup>16&#x02013;23</sup></xref>. Many representatives from these classes have been fully characterised and X-ray crystallographic structures are now known for several (and in some cases many) members of the &#x003b1;-, &#x003b2;-, &#x003b3;-, &#x003b6;- and &#x003b8;- classes<xref rid="CIT0016" ref-type="bibr"><sup>16&#x02013;23</sup></xref>, which constitutes an excellent example of convergent evolution at the molecular level. However, the structures of &#x003b4;-, &#x003b7;- and &#x003b9;-CAs have not yet been reported to date.</p><p>Importantly, the progress in X-ray crystallography over the last few decades has revealed the elusive binding modes of CO<sub>2</sub> and bicarbonate, which are the two main substrates of the enzyme<xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref> (<xref ref-type="fig" rid="F0001">Figure 1)</xref>. Indeed, as seen in <xref ref-type="fig" rid="F0001">Figure 1</xref> for the &#x003b1;-class hCA II, CO<sub>2</sub> is bound in a hydrophobic pocket that is lined with residues Val121, Vals143, Trp209 and Leu198 in close proximity (but not directly coordinated) to the zinc ion, whereas bicarbonate is coordinated to the metal ion in a monodentate fashion. Highly relevant studies from the groups of McKenna and Djinovic-Carugo<xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref> based on high pressure and cryo-crystallographic data demonstrated that the substrate binding modes are probably similar in all CA classes. Such a conclusion was further supported by crystallographic structures of &#x003b2;-CAs by McKenna&#x02019;s group<xref rid="CIT0025" ref-type="bibr"><sup>25</sup></xref>, in which the binding mode of CO<sub>2</sub> to a &#x003b2;-CA expressed in the bacterium <italic>Pseudomonas aeruginosa</italic> (psCA3) was reported.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Active site view of the superimposed hCA II adducts with its main substrates: CO<sub>2</sub> (green, pdb 2VVA) and bicarbonate (pink, pdb 2VVB) <xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref>. The zinc ion is shown as a grey sphere with its three coordinated protein ligands (green/red), His94, 96 and 119. Amino acid residues involved in the binding of the substrates/inhibitors, at the bottom of the active site, are also shown.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1882453_F0001_C"/></fig><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Representation of the superimposed X-ray crystallographic data for hCA II adducts with cyanate (cyan, pdb 4E5Q<xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref>) bromide (magenta, pdb 1RAZ<xref rid="CIT0032" ref-type="bibr"><sup>32</sup></xref>) azide (blue, pdb 1RAY<xref rid="CIT0032" ref-type="bibr"><sup>32</sup></xref>) O<sub>2</sub> (presumably as superoxide anion or radical anion; red, pdb 5EOI<xref rid="CIT0033" ref-type="bibr"><sup>33</sup></xref>) with a tetrahedrally coordinated active site zinc ion (grey sphere). The key active site zinc ligands (His94, 96 and 119) and &#x0201c;gate-keeping&#x0201d; residues (Thr199, Glu106) are also shown.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1882453_F0002_C"/></fig></sec><sec id="S0002" disp-level="1"><label>2.</label><title>Anion inhibitors</title><p>As mentioned above, Lindskog<xref rid="CIT0003" ref-type="bibr"><sup>3&#x02013;5</sup></xref> reported some of the first anion CA inhibition studies, considering the well-known fact that many (in)organic anions have a high affinity for complexing transition metal ions in solution or within the active sites of metalloenzymes<xref rid="CIT0026" ref-type="bibr"><sup>26&#x02013;30</sup></xref>. Such pioneering studies in this field, before the X-ray crystallographic techniques became widely available (i.e. around 1995), used various biophysical techniques, such as circular dichroism, electron paramagnetic spectroscopy (EPR), electronic spectroscopy (UV/Vis), and NMR techniques together with metal-substituted CAs (incorporating Co(II), Cu(II), Mn(II), Ni(II), Cd(II) and other transition metal ions which have the desired spectral/paramagnetic properties, of which Zn<sup>2+</sup>, a d<sup>10</sup> metal ion, is devoid). This allowed the investigation of the interactions of CA with various anions such as cyanide, cyanate, thiocyanate, azide, halides, carboxylates, hydrogen sulphide, and more complex anions (ferrocyanide, ferricyanide, etc.)<xref rid="CIT0027" ref-type="bibr"><sup>27&#x02013;30</sup></xref>. Such interesting and valuable studies were mainly reported by the groups of Coleman<xref rid="CIT0029" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="CIT0030" ref-type="bibr"><sup>30</sup></xref> and Bertini-Scozzafava<xref rid="CIT0027" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="CIT0028" ref-type="bibr"><sup>28</sup></xref>, which reinforced the earlier conclusions<xref rid="CIT0003" ref-type="bibr"><sup>3&#x02013;5</sup></xref> that the anion CAIs coordinate to the metal ion in the enzyme active site in a tetrahedral or more rarely, a trigonal bipyramidal geometry<xref rid="CIT0026" ref-type="bibr"><sup>26&#x02013;30</sup></xref>, as shown schematically in <xref ref-type="fig" rid="F0002">Figure 2</xref> for some anion inhibitors, again using hCA II as model enzyme and high-resolution X-ray crystallography<xref rid="CIT0031" ref-type="bibr"><sup>31&#x02013;33</sup></xref>.</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Representation of the superimposed hCA II adducted to cyanate (cyan, pdb 4E5Q<xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref>) bicarbonate (pink, pdb 2VVB<xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref>) urea (as anion) (white, pdb 1BV3 [39]), and trithiocarbonate (light blue, pdb 3K7K<xref rid="CIT0040" ref-type="bibr"><sup>40</sup></xref>) The zinc ion (grey sphere), its protein ligands (His94, 96 and 119) and gate-keeping residues (Thr199, Glu106) are also shown.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1882453_F0003_C"/></fig><p>Clearly based on the data in <xref ref-type="fig" rid="F0003">Figure 2</xref>, all these anion inhibitors from significantly different chemical classes (e.g. halides, azide, cyanate and even oxygen, presumably bound as anion or radical anion<xref rid="CIT0033" ref-type="bibr"><sup>33</sup></xref>) act as monodentate ligands to the zinc ion, which is in its usual tetrahedral geometry, with three additional ligands (residues His94, His96 and His119). All these (and other) anions have their closest atom to zinc at a distance of about 2&#x02009;&#x000c5;, and most of these anions show a rather low affinity (usually millimolar to micromolar<xref rid="CIT0026" ref-type="bibr"><sup>26</sup></xref>) for this CA isoform. Thus, the zinc remains tetrahedrally coordinated upon inhibition by displacement of a water molecule ligand (or hydroxide) by many different anions. However, in 1993, the results of an X-ray crystallography study performed by the Liljas' group showed that<xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref> cyanate and cyanide (well known &#x0201c;metal poisons&#x0201d;) do not inhibit CAs by this metal binding mechanism but instead are bound at a non-coordinating distance, presumably in the same location that the substrate CO<sub>2</sub> binds (n.b. the CO<sub>2</sub> binding mode was not precisely known at that time). Liljas presented these results in 1992 at an international bioinorganic chemistry conference in Florence prior to their publication in the following year<xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref>, in which many scientists active in the CA field participated. This discovery was considered by many to be a turning point in our understanding of CA inhibition mechanisms. However, these surprising findings presented by Liljas were difficult to rationalise, especially considering the fact that Bertini and Scozzafava&#x02019;s groups, who continued the early research lines pioneered by Lindskog and Coleman, mentioned above<xref rid="CIT0005" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="CIT0029" ref-type="bibr"><sup>29</sup></xref>, presented highly convincing evidence that cyanate and cyanide coordinate to the metal ion (zinc or cobalt) in the CA active site based on data from electronic spectroscopy, EPR and NMR methods<xref rid="CIT0027" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="CIT0028" ref-type="bibr"><sup>28</sup></xref>. One of us (CTS) proposed at the 1992 meeting that cyanate and presumably also cyanide might instead be hydrated by the CA enzyme given that these anions have a shape that is rather similar to that of the substrate CO<sub>2</sub>, hypothesis which has been validated in an interesting computational study by Merz and Banci&#x02019;s groups<xref rid="CIT0035" ref-type="bibr"><sup>35</sup></xref>. Although the eventual experimental validation that CAs can hydrate cyanate and cyanide was more arduous than initially thought, ultimately Maren&#x02019;s group and one of our groups (CTS) demonstrated that this was definitively the case<xref rid="CIT0036" ref-type="bibr"><sup>36</sup></xref>. Maren&#x02019;s laboratory was highly skilled in measuring inhibition constants of anions, including halides, cyanate, cyanide, etc<xref rid="CIT0037" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="CIT0038" ref-type="bibr"><sup>38</sup></xref>. as well as sulphonamides, considering that he was a co-discoverer of several sulphonamide CAIs that have been used clinically for decades as well as the developer of two assay methods based on the CO<sub>2</sub> hydration reaction<xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref>. Maren&#x02019;s group measured the liberation of ammonia from carbamate formed by CA-catalyzed cyanate hydrolysis<xref rid="CIT0036" ref-type="bibr"><sup>36</sup></xref>. Although the ammonia formation was measured, the amount of ammonia was near the limits of detection for the method that was used and no clear-cut conclusions could be drawn. However, we proposed that cyanate once hydrolysed to carbamate within the CA active site may act as a suicide inhibitor, remaining strongly coordinated to the zinc ion<xref rid="CIT0036" ref-type="bibr"><sup>36</sup></xref>, which might also explain the uncommon crystallographic results reported in ref.<xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref> The controversy was resolved years later by McKenna&#x02019;s group<xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref> who reported a high-resolution X-ray crystal structure of hCA II with cyanate bound (<xref ref-type="fig" rid="F0002">Figure 2)</xref>. Cyanate is directly coordinated to the metal ion just like most other anion inhibitors that have been investigated<xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref>. Although this definitive data was published in 2014, which should have &#x0201c;put the debate to rest&#x0201d;, the egregiously incorrect conclusion from the Liljas paper of 1993<xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref> has not yet been rectified by a retraction or correction. Furthermore, the protein database files of the two adducts to hCA II with cyanate and cyanide from Liljas&#x02019;s group have not been deposited in the Protein Database.</p><p>However, this research line ultimately produced some interesting results. Cyanamide (H<sub>2</sub>N-CN or NH&#x02009;=&#x02009;C=NH, as possible tautomers) is another molecule with a similar linear shape with respect to the <italic>sp</italic> hybridised carbon atom as cyanate and CO<sub>2</sub>. Briganti et&#x000a0;al.<xref rid="CIT0039" ref-type="bibr"><sup>39</sup></xref> investigated the role of cyanamide as either a substrate or inhibitor for CAs by using kinetic, electronic spectroscopic and X-ray crystallographic techniques. Again, and to the great surprise, it has been possible to demonstrate that cyanamide is initially acting as a weak inhibitor, which can then undergo a hydration reaction within the enzyme active site resulting in the formation of urea (more precisely the ureate anion), which can remain coordinated to the metal ion, as shown in <xref ref-type="fig" rid="F0003">Figure 3</xref>, in which other structurally-related anions, such as cyanate<xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref>, carbonate<xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref> and trithiocarbonate<xref rid="CIT0040" ref-type="bibr"><sup>40</sup></xref> are also shown superimposed.</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Representation of the binding of A) O<sub>2</sub><sup>&#x02212;</sup> to a Zn<sup>2+</sup>/Cu<sup>2+</sup> hCA II (pdb 5EOI<xref rid="CIT0033" ref-type="bibr"><sup>33</sup></xref>) and B) nitrite to Cu<sup>2+</sup> substituted Cu<sub>2</sub>-hCA II (pdb 6PDV<xref rid="CIT0043" ref-type="bibr"><sup>43</sup></xref>) Distances of the closest atom of the anion to the metal ion are: Zn-O (in the O<sub>2</sub> adduct) of 1.88&#x02009;&#x000c5;; Cu-O (nitrite adduct) of 2.14&#x02009;&#x000c5;.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1882453_F0004_C"/></fig><p>Cyanamide (unlike cyanate) was thus proven to be a new CA substrate, which is not that surprising considering that it is isosteric and isoelectronic with CO<sub>2</sub><xref rid="CIT0039" ref-type="bibr"><sup>39</sup></xref><sub>.</sub> However, the most interesting result was probably that urea could not be displaced from the inhibited enzyme even by using highly effective, low nanomolar sulphonamide inhibitors, which demonstrated that ureate is probably one of the most effective CAIs known to date<xref rid="CIT0039" ref-type="bibr"><sup>39</sup></xref>. It should also be noted that urea (neutral molecule) is a very ineffective inhibitor (no K<sub>I</sub> was measured up to 100&#x02009;mM) probably because it cannot be readily deprotonated in aqueous solutions for enzyme measurement assays<xref rid="CIT0039" ref-type="bibr"><sup>39</sup></xref>. Thus, only the deprotonated form, which is formed <italic>in situ</italic> through the suicide inhibition effects of cyanamide acts as a CAI, which is in fact the situation we expected (but could not initially confirm) for cyanate. As seen in <xref ref-type="fig" rid="F0004">Figure 3</xref>, cyanate, carbonate and trithiocarbonate (all zinc binders) do not completely overlap in the X-ray crystal structures but they bind in a similar fashion, being monodentate ligands of the Zn(II) ion, which is in its stable tetrahedral geometry<xref rid="CIT0024" ref-type="bibr"><sup>24</sup></xref><sup>,</sup><xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="CIT0040" ref-type="bibr"><sup>40</sup></xref>. The same geometry was observed also for the ureate adduct (<xref ref-type="fig" rid="F0004">Figure 3</xref>) and it was also bound in a monodentate fashion like many other small anions that have been reported to date. However, the ureate is tilted and has a very different orientation towards the gate-keeping residues Glu106-Thr199<xref rid="CIT0039" ref-type="bibr"><sup>39</sup></xref>. In a subsequent study<xref rid="CIT0041" ref-type="bibr"><sup>41</sup></xref>, by using cryo-crystallography, it has been possible to &#x0201c;freeze&#x0201d; and observe the formation of the intermediates in the CA-catalyzed cyanamide hydration reaction, which revealed a new proposed reaction mechanism for this hydrolytic process.</p><p>Apart the active site metal ion, hCA II has an additional metal binding site, at its entrance<xref rid="CIT0042" ref-type="bibr"><sup>42</sup></xref>. Copper(II) binds rather efficiently in this additional site, being coordinated by His64, His4 and several water molecules<xref rid="CIT0033" ref-type="bibr"><sup>33</sup></xref><sup>,</sup><xref rid="CIT0042" ref-type="bibr"><sup>42</sup></xref>. This form of the enzyme, with Zn(II) at its active site and Cu(II) at the secondary site is referred to as Zn/Cu-hCA II, in contrast to the enzyme which has zinc substituted by copper also within the catalytic centre (Cu<sub>2</sub>-hCA II)<xref rid="CIT0043" ref-type="bibr"><sup>43</sup></xref>. Recently, McKenna&#x02019;s group proposed that the Cu<sub>2</sub>-hCA II also has nitrite reductase activity, with nitrite being initially coordinated (as a bidentate ligand) to the active site copper ion (<xref ref-type="fig" rid="F0004">Figure 4(B)</xref>). In contrast, as mentioned also above, the Zn/Cu-hCA II was observed with an O<sub>2</sub> molecule coordinated to zinc (<xref ref-type="fig" rid="F0004">Figure 4(B)</xref>), which most probably is a superoxide anion (or anion radical), as suggested by computational techniques<xref rid="CIT0033" ref-type="bibr"><sup>33</sup></xref>. A major overall conclusion is that all serious studies performed to date on hCA II demonstrate that anions are coordinated to the metal ion in the enzyme active site.</p></sec><sec id="S0003" disp-level="1"><label>3.</label><title>Sulphonamides and other zinc binders, the tail approach</title><p>Primary sulphonamides<xref rid="CIT0044" ref-type="bibr"><sup>44&#x02013;46</sup></xref> were known for decades<xref rid="CIT0008" ref-type="bibr"><sup>8&#x02013;10</sup></xref> to potently inhibit CAs by binding as RSO<sub>2</sub>NH<sup>-</sup> anions to the Zn(II) ion within the enzyme active site, as shown by using various spectroscopic techniques<xref rid="CIT0005" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="CIT0012" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="CIT0013" ref-type="bibr"><sup>13</sup></xref><sup>,</sup><xref rid="CIT0030" ref-type="bibr"><sup>30</sup></xref> as well as a crystallographic study from Liljas&#x02019; group, in which acetazolamide <bold>1</bold>, and 3-acetoxymercuri-4-aminobenzenesulfonamide <bold>2</bold> (<xref ref-type="fig" rid="F0009">Chart 1</xref>), and the anion thiocyanate, were crystallised in complexes with hCA II<xref rid="CIT0047" ref-type="bibr"><sup>47</sup></xref>. As for the anions mentioned in the preceding paragraphs, the sulphonamide inhibitors substituted the water/hydroxide ion acting as the fourth ligand to the tetrahedrally coordinated zinc site in a monodentate coordination with the metal ion through the deprotonated nitrogen atom of the sulphonamide moiety, resulting in a favourable hydrogen bond with Thr199, a conserved residue in most &#x003b1;-CAs. In contrast, thiocyanate binding was reported to result in a trigonal-bipyramidal coordination of the zinc centre because SCN<sup>-</sup> added to the coordination sphere of the non-inhibited enzyme<xref rid="CIT0047" ref-type="bibr"><sup>47</sup></xref>. Since then, hundreds of sulphonamides were crystallised in complexes with various CA isoforms and in all of them the sulphonamide zinc-binding group (ZBG) participates in the same interactions as mentioned above for acetazolamide (reviewed in refs.<xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref><sup>,</sup><xref rid="CIT0048" ref-type="bibr"><sup>48</sup></xref>).</p><p>Although acetazolamide and other first generation sulphonamide CAIs (such as methazolamide, ethoxzolamide, dichlorophenamide, etc.; refer to refs.<xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="CIT0012" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref> for their structures) are potent, low nanomolar CAIs, they are non-selective inhibitors<xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref>, strongly inhibiting most hCA isoforms that are known to date (12 catalytically active isoforms that have been reported, hCA I-VA, VB, VI, VII, IX, XII-XIV<xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="CIT0012" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref>) As a consequence, the first- and even second-generation inhibitors used clinically resulted in a range of documented side effects connected to the inhibition of off-target isoforms<xref rid="CIT0048" ref-type="bibr"><sup>48&#x02013;57</sup></xref>.</p><p>For such reasons, designing isoform-selective CAIs became the main issue in the revival of the CA field in the mid to late 90&#x02009;s for obtaining compounds with an improved safety profile and efficacy compared to the inhibitors available at that time<xref rid="CIT0058" ref-type="bibr"><sup>58&#x02013;60</sup></xref>. The tail approach has thus emerged in that period as an innovative modality for developing CA-selective inhibitors<xref rid="CIT0061" ref-type="bibr"><sup>61</sup></xref>. The idea is very simple: the attachment of moieties that may induce the desired physico-chemical properties (e.g. enhanced hydro- or liposolubility) to scaffolds of simple aromatic/heterocyclic sulphonamides (e.g. sulphanilamide, metanilamide, orthanilamide, and their derivatives; 5-amino-1,3,4-thiadiazole-2-sulphonamide, 4-methyl-5-imino-1,3,4-thiadiazoline-2-sulphonamide, and many other simple sulphonamides etc.) might lead to interactions with the external part of the CA active site, and not only with residues near the zinc catalytic centre that are the most highly conserved in all hCA isoforms. Indeed, the region at the entrance of the active site cavity is the most variable between the different human isoforms<xref rid="CIT0061" ref-type="bibr"><sup>61</sup></xref>. Detailed kinetic studies were thereafter performed on over 10,000 different sulphonamide derivatives<xref rid="CIT0062" ref-type="bibr"><sup>62&#x02013;71</sup></xref>, which were synthesised and investigated in our laboratories and an additional 15,000 derivatives were received from academic groups and pharmaceutical companies in collaboration with the Florence group. Crystallography in complex with various isoforms was done on several hundred such derivatives. This type of research demonstrated that the hypothesis was correct and that it is possible to design sulphonamide CAIs that are selective for each isoform of interest by tailoring the dimensions (length, bulkiness, etc.) as well as the chemical nature of the various tails<xref rid="CIT0061" ref-type="bibr"><sup>61&#x02013;71</sup></xref>. This research led to the discovery of many new sulphonamide, sulfamate and sulfamide classes, including the ureido-benzene-sulphonamides<xref rid="CIT0070" ref-type="bibr"><sup>70</sup></xref><sup>,</sup><xref rid="CIT0072" ref-type="bibr"><sup>72</sup></xref> as well as derivatives possessing more than one tail attached to the scaffold, such as dual-tailed or tri-tailed CAIs<xref rid="CIT0073" ref-type="bibr"><sup>73</sup></xref><sup>,</sup><xref rid="CIT0074" ref-type="bibr"><sup>74</sup></xref>. Of the many compounds discovered in this way includes SLC-0111, compound <bold>3</bold>, which is a CA IX/XII-selective inhibitor that is now in clinical trials as an antitumor/antimetastatic agent (see discussion later in the text). Another notable example is the three-tailed sulphonamide <bold>4</bold> (<xref ref-type="fig" rid="F0001">Chart 1</xref>).<xref rid="CIT0071" ref-type="bibr"><sup>71</sup></xref> Both SLC-0111 and sulphonamide <bold>4</bold> strongly inhibit and bind to hCA IX (<xref ref-type="fig" rid="F0005">Figure 5</xref>)<xref rid="CIT0071" ref-type="bibr"><sup>71,74</sup></xref>.</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Active site view of A) hCA IX catalytic domain adducted to SLC-0111 (magenta)<xref rid="CIT0074" ref-type="bibr"><sup>74</sup></xref> and B) hCA II adducted to the three tailed inhibitor <bold>4</bold> (in green).<xref rid="CIT0071" ref-type="bibr"><sup>71</sup></xref> H-bonds are represented as black dashed lines. The Zn(II) ion (grey sphere) and some important amino acid residues involved in the binding of inhibitors are shown.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1882453_F0005_C"/></fig><fig id="F0006" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>Historical overview on the discovery of the main chemotypes with CA inhibitory activity.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1882453_F0006_C"/></fig><p>The tail approach was virtually the only strategy used to obtain CAIs from the moment it was disclosed, and it has been adopted by research groups all over the world<xref rid="CIT0071" ref-type="bibr"><sup>71</sup></xref><sup>,</sup><xref rid="CIT0075" ref-type="bibr"><sup>75&#x02013;91</sup></xref>. For space reasons only a limited number of such research was cited here, as the field was recently reviewed<xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref><sup>,</sup><xref rid="CIT0048" ref-type="bibr"><sup>48</sup></xref>. The advantage of the tail approach over other strategies to obtain isoform-selective CAIs are the facility of the syntheses, the versatility and possibility to introduce a variety of tails/scaffolds with different chemical properties, and thus to generate chemical diversity. As a consequence, these procedures were extended to many other classes of CAIs, not only to the sulphonamides and their isosteres (sulfamides/sulfamates, which are not discussed here in details; see refs.<xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref><sup>,</sup><xref rid="CIT0048" ref-type="bibr"><sup>48</sup></xref> for recent reviews). These new chemotypes will be discussed in the next paragraph, together with some new CA inhibition mechanisms which emerged more recently.</p></sec><sec id="S0004" disp-level="1"><label>4.</label><title>Other chemotypes with CA inhibitory power</title><p>By comparing the sulphur-based, carbon-based<xref rid="CIT0045" ref-type="bibr"><sup>45</sup></xref> and phosphorus-based ZBGs, a range of novel classes of non-sulphonamide CAIs which interact with the zinc ion were reported, including phosphonamidates<xref rid="CIT0091" ref-type="bibr"><sup>91</sup></xref>, dithiocarbamates<xref rid="CIT0092" ref-type="bibr"><sup>92</sup></xref> and their derivatives (monothiocarbamates<xref rid="CIT0093" ref-type="bibr"><sup>93</sup></xref>, xanthates and trithiocarbonates<xref rid="CIT0094" ref-type="bibr"><sup>94</sup></xref>) selenols<xref rid="CIT0095" ref-type="bibr"><sup>95</sup></xref><sup>,</sup><xref rid="CIT0096" ref-type="bibr"><sup>96</sup></xref>, carboxylates<xref rid="CIT0097" ref-type="bibr"><sup>97</sup></xref>, hydroxamates<xref rid="CIT0098" ref-type="bibr"><sup>98</sup></xref>, benzoxaboroles<xref rid="CIT0099" ref-type="bibr"><sup>99&#x02013;101</sup></xref>, and carbamates<xref rid="CIT0102" ref-type="bibr"><sup>102</sup></xref>. In addition, other classes of inhibitors that have been developed which exhibit a different inhibition mechanism compared to the zinc binders discussed above. It should be noted that many of the new chemotypes bind further away from the metal ion, interacting both with the hydrophobic and hydrophilic halves of the CA active site<xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref><sup>,</sup><xref rid="CIT0048" ref-type="bibr"><sup>48</sup></xref>. These new inhibition mechanisms include:<list list-type="roman-lower"><list-item><p>CAIs that anchor to the zinc-coordinated water molecule<xref rid="CIT0103" ref-type="bibr"><sup>103</sup></xref><sup>,</sup><xref rid="CIT0104" ref-type="bibr"><sup>104</sup></xref>. Polyamines, such as spermine and its derivatives<xref rid="CIT0103" ref-type="bibr"><sup>103</sup></xref>, the simple phenol<xref rid="CIT0104" ref-type="bibr"><sup>104</sup></xref> and many of its derivatives<xref rid="CIT0105" ref-type="bibr"><sup>105&#x02013;108</sup></xref> together with polyphenols<xref rid="CIT0109" ref-type="bibr"><sup>109</sup></xref> inhibit CAs in this way. This inhibition mechanism is also shared by the sulfocoumarins and their derivatives, as demonstrated by Zalubovskis group<xref rid="CIT0110" ref-type="bibr"><sup>110&#x02013;113</sup></xref> using kinetic and crystallographic studies. These classes of highly innovative CAIs were developed by the Riga group<xref rid="CIT0110" ref-type="bibr"><sup>110&#x02013;113</sup></xref> starting from coumarins and their derivatives as a class of inhibitors with a totally new inhibition mechanism, which has been unravelled by some of us<xref rid="CIT0114" ref-type="bibr"><sup>114&#x02013;124</sup></xref>. Thioxocoumarins are the only exception, as they bind similar to the phenols, anchoring with their exocyclic sulphur atom to the zinc coordinated water molecule<xref rid="CIT0114" ref-type="bibr"><sup>114</sup></xref>.</p></list-item><list-item><p>Coumarins and many of their derivatives such as mono- and dithio-, as well as seleno/tellurium-coumarins but also many other structurally related compounds<xref rid="CIT0115" ref-type="bibr"><sup>115&#x02013;124</sup></xref> were shown to possess a very particular inhibition mechanism. This was demonstrated for the simple coumarin <bold>5</bold> and one of its derivative (compound <bold>6</bold>), a natural product isolated from the Australian plant <italic>Leionema ellipticum</italic><xref rid="CIT0115" ref-type="bibr"><sup>115</sup></xref><sup>,</sup><xref rid="CIT0116" ref-type="bibr"><sup>116</sup></xref>. The lactone ring of the coumarin is hydrolysed by the esterase activity of CA, leading to the formation of <italic>cis</italic>- or <italic>trans</italic>-2-hydroxycinnamic acid derivatives, of types <bold>7</bold> and <bold>8</bold> (<xref ref-type="fig" rid="F0001">Chart 1</xref>), which thereafter bind far from the zinc ion, at the entrance of the active site cavity (the region which is more variable among the different human isoforms, as mentioned above). As a consequence, coumarins and their derivatives behave as pro-drug inhibitors, but also show a very high selectivity for many CA isoforms, depending on the substitution pattern on their bicyclic ring system<xref rid="CIT0115" ref-type="bibr"><sup>115&#x02013;124</sup></xref>. Many representatives belonging to this family of CAIs in fact possess extremely good selectivity ratios for inhibiting isoforms of interest (e.g. CA IX and XII) versus highly distributed, &#x0201c;house-keeping&#x0201d; off-target isoforms, such as CA I and II<xref rid="CIT0115" ref-type="bibr"><sup>115&#x02013;124</sup></xref>.</p></list-item><list-item><p>Probably one of the strangest CA inhibition mechanism is the one reported by De Simone&#x02019;s and Carradori&#x02019;s group for a benzoic acid derivative (compound <bold>9</bold>) which binds outside the active site cavity, blocking the His64 residue (the proton shuttle residue) in its <italic>out</italic> conformation<xref rid="CIT0125" ref-type="bibr"><sup>125</sup></xref>. Again, X-ray crystallography was crucial for demonstrating this highly interesting CA inhibition mechanism.</p></list-item></list></p><p>An overview of the main new chemotypes acting as CAIs discovered up until now is shown in <xref ref-type="fig" rid="F0006">Figure 6</xref>, in which the &#x0201c;fresh&#x0201d; discovery of the ninhydrins is also mentioned<xref rid="CIT0126" ref-type="bibr"><sup>126</sup></xref>. Indeed, ninhydrins, such as compound <bold>10</bold>, possess a <italic>gem</italic>-diol stable functionality which has been shown by means of kinetic and computational techniques to coordinate to the metal ion from the enzyme active site<xref rid="CIT0126" ref-type="bibr"><sup>126</sup></xref>. Furthermore, <xref ref-type="fig" rid="F0007">Figure 7</xref> shows the X-ray crystal structures of some of the new chemotypes detected in the last period, such as the selenol <bold>11</bold><xref rid="CIT0095" ref-type="bibr"><sup>95</sup></xref> (<xref ref-type="fig" rid="F0007">Figure 7(A)</xref>), unsubstituted ninhydrin <bold>10</bold><xref rid="CIT0126" ref-type="bibr"><sup>126</sup></xref> (<xref ref-type="fig" rid="F0007">Figure 7(B)</xref>) and a catechol derivative <bold>12</bold><xref rid="CIT0127" ref-type="bibr"><sup>127</sup></xref> (<xref ref-type="fig" rid="F0007">Figure 7(C)</xref>) which has been recently reported to bind to hCA II by a new inhibition mechanism. Like many phenols, the catechol <bold>12</bold> is anchored to the zinc-coordinated water molecule, but being a diphenol, the second OH moiety additionally binds to the &#x0201c;deep water&#x0201d; molecule in the active site. As mentioned above, selenol <bold>11</bold> and the ninhydrin <bold>10</bold> (<xref ref-type="fig" rid="F0001">Chart 1</xref>) directly coordinate to the zinc ion in the enzyme active site (<xref ref-type="fig" rid="F0007">Figure 7)</xref>. Many of these inhibition mechanisms were thoroughly reviewed in ref.<xref rid="CIT0128" ref-type="bibr"><sup>128</sup></xref>.</p><fig id="F0007" orientation="portrait" position="float"><label>Figure 7.</label><caption><p>Active site view of hCA II complexed to A) selenol <bold>11</bold> (pdb 6hX5) <xref rid="CIT0096" ref-type="bibr"><sup>96</sup></xref>, B) ninhydrin <bold>10</bold> (predicted <italic>in silico</italic>)<xref rid="CIT0127" ref-type="bibr"><sup>127</sup></xref> and C) catechol derivative <bold>12</bold> (pdb 6YRI) <xref rid="CIT0128" ref-type="bibr"><sup>128</sup></xref>. H-bonds are represented as black dashed lines. The Zn(II) ion (grey sphere) and residues involved in its coordination and some active site residues near the binding of inhibitors are shown in CPK colours. Water molecules are shown as red spheres.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1882453_F0007_C"/></fig><fig id="F0008" orientation="portrait" position="float"><label>Figure 8.</label><caption><p>hCAs as drug targets<xref rid="CIT0011" ref-type="bibr"><sup>11</sup></xref><sup>,</sup><xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref><sup>,</sup><xref rid="CIT0051" ref-type="bibr"><sup>51&#x02013;57</sup></xref>. From edoema and glaucoma, to obesity, neuropathic pain, hypoxic cancers, cerebrovascular diseases and oxidative stress, many isoforms are involved in diverse pathologies for which isoform-selective inhibitors showed a relevant potential to be translated to clinical entities.</p></caption><graphic content-type="color" xlink:href="IENZ_A_1882453_F0008_C"/></fig></sec><sec id="S0005" disp-level="1"><label>5.</label><title>New applications of the CAIs</title><p>For the last 65&#x02009;years the CAIs were used as diuretics<xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="CIT0051" ref-type="bibr"><sup>51</sup></xref><sup>,</sup><xref rid="CIT0053" ref-type="bibr"><sup>53</sup></xref><sup>,</sup><xref rid="CIT0055" ref-type="bibr"><sup>55</sup></xref> and anti-glaucoma agents<xref rid="CIT0002" ref-type="bibr"><sup>2</sup></xref><sup>,</sup><xref rid="CIT0056" ref-type="bibr"><sup>56&#x02013;59</sup></xref>, and they still have a firm place for the management of these conditions<xref rid="CIT0053" ref-type="bibr"><sup>53</sup></xref><sup>,</sup><xref rid="CIT0057" ref-type="bibr"><sup>57</sup></xref>. However, in the last decade, several other highly relevant applications emerged, probably due to the availability of much more isoform-selective inhibitors. They include the use of CAIs such as acetazolamide <bold>1</bold>, topiramate <bold>13</bold> and zonisamide <bold>14</bold> as antiepileptics<xref rid="CIT0129" ref-type="bibr"><sup>129</sup></xref><sup>,</sup><xref rid="CIT0130" ref-type="bibr"><sup>130</sup></xref> and anti-obesity agents<xref rid="CIT0054" ref-type="bibr"><sup>54</sup></xref><sup>,</sup><xref rid="CIT0131" ref-type="bibr"><sup>131</sup></xref><sup>,</sup><xref rid="CIT0132" ref-type="bibr"><sup>132</sup></xref>, targeting diverse isoforms (CA II and VII for the antiepileptic use, and CA VA/VB as antiobesity agents) <xref rid="CIT0129" ref-type="bibr"><sup>129&#x02013;132</sup></xref>. In fact, as seen from <xref ref-type="fig" rid="F0008">Figure 8</xref>, most of the CA isoforms, alone (or in combinations of few of them) possess therapeutic/pharmacological applications.</p><fig id="F0009" orientation="portrait" position="float"><label>Chart 1.</label><caption><p>Structure of the compounds <bold>1&#x02013;14</bold> discussed in this review.</p></caption><graphic content-type="black-white" xlink:href="IENZ_A_1882453_F0009_B"/></fig><p>In fact, nowadays the CAIs were proposed to be used or are already used for the management of the following pathologies, in addition to the classical ones mentioned above: (i) treatment of idiopathic intracranial hypertension, by targeting hCA I and II but presumably also brain/cerebrospinal fluid isoforms<xref rid="CIT0133" ref-type="bibr"><sup>133</sup></xref>; (ii) cerebral ischemia/diabetic cerebrovascular pathologies (the targeted isoforms seem to be hCA IX and XII, possibly also hCA VA)<xref rid="CIT0134" ref-type="bibr"><sup>134</sup></xref>; (iii) neuropathic pain, by targeting the bran/peripheral nervous system isoforms hCA II and VII<xref rid="CIT0135" ref-type="bibr"><sup>135</sup></xref><sup>,</sup><xref rid="CIT0136" ref-type="bibr"><sup>136</sup></xref>; (iv) inflammation/arthritis, by targeting hCA IX/XII and possibly hCA IV<xref rid="CIT0137" ref-type="bibr"><sup>137&#x02013;140</sup></xref>; (v) hypoxic tumours, by targeting the two isoforms discovered to be associated with tumours, hCA IX<xref rid="CIT0141" ref-type="bibr"><sup>141</sup></xref> and hCA XII<xref rid="CIT0142" ref-type="bibr"><sup>142</sup></xref>. This is in fact the field in which the highest number of studies have been published in the last decades<xref rid="CIT0143" ref-type="bibr"><sup>143&#x02013;155</sup></xref>. Most of the proof-of-concept studies which validated the various isoforms for the management of such widespread diseases were conducted either in Florence or by collaborations with well-known groups worldwide, which used the compounds developed in Florence for these studies. Highly important for the success of these investigations was the fact that the X-ray crystal structures of almost all hCA isoforms (except hCA VB, X and XI) were published in the last 15&#x02009;years<xref rid="CIT0156" ref-type="bibr"><sup>156&#x02013;161</sup></xref>. This allowed for highly focussed drug design campaigns in order to obtain isoform-selective compounds for all these enzymes, and again using the tail approach<xref rid="CIT0061" ref-type="bibr"><sup>61</sup></xref> and a variety of newly discovered chemotypes, discussed above, were essential for the success of these efforts.</p></sec><sec id="S0006" disp-level="1"><label>6.</label><title>CA activators and their applications</title><p>The carbonic anhydrase activators (CAAs) have been the focus of significant controversy for a long time up until 1997 when the first X-ray crystal structure of a complex of an activator (histamine) bound to hCA II was reported and the activation mechanism was revealed in molecular level detail<xref rid="CIT0162" ref-type="bibr"><sup>162</sup></xref>. The activator, which was observed to be directly bound within the enzyme active site, promotes the formation of an enzyme &#x02013; activator complex, in which the proton shuttling moieties present in the activator participate in the rate-determining step of the catalytic cycle, i.e. the transfer of a proton from the zinc-coordinated water to the external reaction medium, similar to the natural proton shuttle, which is residue His64 (in many CA isoforms), as mentioned above<xref rid="CIT0162" ref-type="bibr"><sup>162</sup></xref><sup>,</sup><xref rid="CIT0163" ref-type="bibr"><sup>163</sup></xref>. In such enzyme-activator complexes, the proton transfer is intramolecular, being more efficient compared to the intermolecular transfer to buffer molecules, which are not bound within the enzyme cavity<xref rid="CIT0162" ref-type="bibr"><sup>162</sup></xref><sup>,</sup><xref rid="CIT0163" ref-type="bibr"><sup>163</sup></xref>. Many X-ray crystal structures with amines and amino acid activators were reported thereafter, in addition to histamine<xref rid="CIT0162" ref-type="bibr"><sup>162</sup></xref>, including L- and D-His bound to hCA II and hCA I, L- and D-Phe, D-Trp, L-adrenaline and pyridinium derivatives of histamine bound to hCA II, which confirmed this general CA activation mechanism outlined above<xref rid="CIT0164" ref-type="bibr"><sup>164&#x02013;167</sup></xref>. The thirteen catalytically active mammalian CAs (e.g. CA I-VA, VB, VI, VII, IX, XII-XV) were also investigated for their interaction with a rather large library of amino acids and amines<xref rid="CIT0168" ref-type="bibr"><sup>168</sup></xref><sup>,</sup><xref rid="CIT0169" ref-type="bibr"><sup>169</sup></xref>, whereas several drug design studies have also been performed<xref rid="CIT0170" ref-type="bibr"><sup>170&#x02013;174</sup></xref>. Why are these studies relevant? In the last few years it has been demonstrated that CAAs of the amino acid type (e.g. D-Phe) can enhance memory and learning, which is antagonised by the simultaneous administration of a CAI of the sulphonamide type (e.g. acetazolamide) <xref rid="CIT0175" ref-type="bibr"><sup>175</sup></xref>. A recent study showed that administration of the D-Phe to rats rapidly activated the extracellular signal-regulated kinase (ERK) pathways, which are involved in critical steps of memory formation, both in the cortex and the hippocampus, two brain areas crucially involved in memory processing<xref rid="CIT0175" ref-type="bibr"><sup>175</sup></xref><sup>,</sup><xref rid="CIT0176" ref-type="bibr"><sup>176</sup></xref>. Even more recently, the same groups (including the Florence team) demonstrated that CAAs play a crucial role in extinction of contextual fear memory<xref rid="CIT0177" ref-type="bibr"><sup>177</sup></xref>, opening the way towards the validation of CAs as new targets for improving cognition, but also in therapeutic areas, such as phobias, obsessive-compulsive disorder, generalised anxiety, and post-traumatic stress disorders, for which few efficient therapies are available to date<xref rid="CIT0175" ref-type="bibr"><sup>175&#x02013;177</sup></xref>.</p></sec><sec id="S0007" disp-level="1"><label>7.</label><title>Discussion and conclusions</title><p>The drug design landscape for modulators of CA activity, both inhibitors and activators, appears to be a dynamic and healthy field, in which many relevant advances have been achieved in the last several decades through continuous contributions from many research groups, as outlined above. However, recently an event disturbed this situation. In an egregious polemic from Jonsson and Liljas<xref rid="CIT0178" ref-type="bibr"><sup>178</sup></xref>, the measurements of some CA inhibition data were queried, in addition to some other aspects that will be discussed later in this article. This action was based on some typographical errors found in Supplementary Information from 5 papers from our group (among the &#x0003e; 1600 that have been published). We have replied to the above-mentioned article<xref rid="CIT0178" ref-type="bibr"><sup>178</sup></xref> in an Editorial published in the same journal<xref rid="CIT0179" ref-type="bibr"><sup>179</sup></xref> as well as two additional review articles<xref rid="CIT0153" ref-type="bibr"><sup>153</sup></xref><sup>,</sup><xref rid="CIT0180" ref-type="bibr"><sup>180</sup></xref>. Jonsson and Liljas replied to our editorial<xref rid="CIT0179" ref-type="bibr"><sup>179</sup></xref> with a new comment published recently<xref rid="CIT0181" ref-type="bibr"><sup>181</sup></xref>. Furthermore, Liljas &#x0201c;promoted&#x0201d; their initial article<xref rid="CIT0178" ref-type="bibr"><sup>178</sup></xref> by writing a denigrating and arrogant letter to the president of the University of Florence about one of us (CTS), stating that he is, &#x0201c;<italic>bothered about how long his</italic> [Supuran&#x02019;s] <italic>poorly performed science could continue without serious criticism</italic>&#x0201d;, and &#x0201c;<italic>I followed Supuran's crystallographic investigations with horror</italic>&#x0201d;, but no technical comments regarding our presumed crystallographic errors were mentioned in this letter or in their papers, although Liljas himself is a crystallographer. We worked in this field in collaboration with well-established crystallographers from several laboratories in Italy, Germany, USA, Australia and Singapore over the years<xref rid="CIT0178" ref-type="bibr"><sup>178</sup></xref>. Liljas continued, &#x0201c;<italic>the measurements are so poorly done that an undergraduate student reporting these in his works should have failed</italic>&#x0201d; and &#x0201c;<italic>we tried to publish our manuscript in the journals where Supuran has published his work but failed. This covers a good number of journals</italic>&#x0201d;, meaning probably that serious journals did not take into consideration his poorly formulated polemic. Liljas ends his letter to the rector: &#x0201c;<italic>The work by Supuran that we criticise needs to be repeated. There may be really excellent inhibitors among the hundreds of compounds that he has studied, but his analysis does not give a trustworthy account. It is important that the field and his co-workers become fully aware of the quality of his analyses and to know that much has to be done again</italic>&#x0201d;. In other words, this scientist who published completely erroneous conclusions based on crystallography data as shown here for the cyanate and cyanide examples<xref rid="CIT0034" ref-type="bibr"><sup>34</sup></xref> and elsewhere by others<xref rid="CIT0031" ref-type="bibr"><sup>31</sup></xref> and who has not withdrawn or corrected these published results after 27&#x02009;years, finds it insufficient to publish his conceptually erroneous polemic<xref rid="CIT0178" ref-type="bibr"><sup>178</sup></xref>, but also wants to defame our group to our institution. We have replied to the technical issues raised by Jonsson and Liljas, as mentioned above. In their comment on our reply<xref rid="CIT0180" ref-type="bibr"><sup>180</sup></xref> they indicated they were &#x0201c;<italic>happy by our prompt response</italic>&#x0201d; and that some clarifications were achieved<xref rid="CIT0181" ref-type="bibr"><sup>181</sup></xref>, however now their criticism relating to the measurement of inhibition constants was extended to the entire medicinal chemistry community, not only to our group, stating that the &#x0201c;<italic>original article was not intended to raise specific concerns regarding just one research group but rather was intended to raise concerns regarding medicinal chemistry publications in general, and we are glad that Prof. Supuran agrees that there is room for improvement!</italic>&#x0201d; CTS hardly agrees with anything from their analysis. Such a strong and prejudicial opinion from someone without experience in the medicinal chemistry field is disappointing. Notably, the &#x0201c;best practice&#x0201d; examples for the measurement of K<sub>I</sub>s that Jonsson and Liljas provide in their reply<xref rid="CIT0181" ref-type="bibr"><sup>181</sup></xref> are the highly controversial articles from Johnson &#x00026; Johnson regarding topiramate <bold>13</bold><xref rid="CIT0182" ref-type="bibr"><sup>182&#x02013;185</sup></xref>. Indeed, topiramate was initially reported to not be a CAI<xref rid="CIT0182" ref-type="bibr"><sup>182</sup></xref>, then a millimolar inhibitor<xref rid="CIT0183" ref-type="bibr"><sup>183</sup></xref>, then a micromolar inhibitor<xref rid="CIT0184" ref-type="bibr"><sup>184</sup></xref> until finally it was established to be a sub-micromolar inhibitor<xref rid="CIT0185" ref-type="bibr"><sup>185</sup></xref> by the same group of Johnson &#x00026; Johnson who initially discovered the compound. We have reported the X-ray crystal structure of this important drug bound to hCA II and demonstrated that it is a low nanomolar inhibitor for many CA isoforms<xref rid="CIT0186" ref-type="bibr"><sup>186</sup></xref>. There are also other unusual comments from Jonsson and Liljas<xref rid="CIT0181" ref-type="bibr"><sup>181</sup></xref> regarding the native mass spectrometry measurements. Presumably, the main issue with this method is that it can be used to measure dissociation constants that are in very good agreement with the stopped flow method used in Florence, in addition to other methods such as isothermal titration calorimetry (ITC) and differential scanning calorimetry (DSC)<xref rid="CIT0187" ref-type="bibr"><sup>187</sup></xref><sup>,</sup><xref rid="CIT0188" ref-type="bibr"><sup>188</sup></xref>.</p><p>As noted above, there are no original contributions in the literature from Jonsson and/or Liljas regarding the measurement of inhibition constants (for CAs or any other enzyme) nor for any drug design studies targeting CAs or other druggable proteins. Jonsson is a biochemist who published several papers in the CA field and Liljas was a crystallographer (now retired for some time), who, as we mentioned earlier, contributed some important X-ray crystallographic studies in the 70&#x02009;s and 80&#x02009;s on CAs and then some questionable CA data in the 90&#x02009;s (as discussed above). It should be noted that there is no analysis at all of our crystallographic work in the two papers by Jonsson and Liljas<xref rid="CIT0178" ref-type="bibr"><sup>178</sup></xref><sup>,</sup><xref rid="CIT0181" ref-type="bibr"><sup>181</sup></xref> or in the letter to the rector, from more than 250 papers that we have published in that field, as mentioned here and elsewhere<xref rid="CIT0012" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="CIT0014" ref-type="bibr"><sup>14</sup></xref>. However, the polemic by Jonsson and Liljas<xref rid="CIT0178" ref-type="bibr"><sup>178</sup></xref> has been supported by another scientist, Matulis, based on his recent reference to this work<xref rid="CIT0189" ref-type="bibr"><sup>189</sup></xref>.</p><p>Matulis entered the CA field in 2005 when he published his first paper with the Johnson &#x00026; Johnson group<xref rid="CIT0190" ref-type="bibr"><sup>190</sup></xref>, on a fluorescent thermal shift assay (FTSA) for measuring CA inhibition. In this method, the extent of protein unfolding is monitored as a function to temperature when heated, alone and in the presence of inhibitors, providing a way to measure the affinity of inhibitors as well as some thermodynamic parameters. This method requires high concentrations of enzyme (around 5&#x02013;10&#x02009;&#x000b5;M), it uses a very high concentration (50&#x02009;&#x000b5;M) of a fluorescent dye, ANS (8-anilino-1-naphthalene-sulphonate) as well as a 50&#x02009;mM phosphate buffer<xref rid="CIT0190" ref-type="bibr"><sup>190</sup></xref>. We and others have demonstrated that sulphonates can be strong inhibitors of the CAs<xref rid="CIT0110" ref-type="bibr"><sup>110</sup></xref>, and phosphate is also an anion CA inhibitor<xref rid="CIT0026" ref-type="bibr"><sup>26</sup></xref>. Just recently one of us (AA) retested phosphate as an inhibitor of hCA I and II at a concentration of 10&#x02009;nM to 100&#x02009;mM by the stopped-flow assay. At 50&#x02009;mM, an inhibition of 13.0% of the activity of hCA I and 19.1% of the activity of hCA II was measured (unpublished results from our laboratories). Thus, the competition of the buffer, dye and inhibitor for binding to the metal ion (or elsewhere in the CA active site), coupled with the large concentrations of enzyme that is required results in this method providing information of limited usefulness regarding CA activity. FTSA was however extensively used in the subsequent Matulis papers, in combination with ITC, which as mentioned by Linkuviene et&#x000a0;al. is one of the &#x0201c;most robust techniques&#x0201d; for measuring interactions between proteins and small molecule ligands in drug design<xref rid="CIT0191" ref-type="bibr"><sup>191</sup></xref>. ITC also uses high concentrations of enzymes in the assay system (6&#x02013;20&#x02009;&#x000b5;M), and as mentioned in the Matulis papers the buffer is again 50&#x02009;mM phosphate plus 100&#x02009;mM NaCl. In addition to phosphate, chloride is also a CAI that binds to the metal ion active site<xref rid="CIT0026" ref-type="bibr"><sup>26</sup></xref>. Chloride is even more inhibitory than phosphate, as documented earlier by many groups. The K<sub>I</sub> of this anion is 6&#x02009;mM against hCA I, 200&#x02009;mM against hCA II, 1.8&#x02009;mM against hCA VII, 138&#x02009;mM against mCA XIII (m&#x02009;=&#x02009;murine enzyme), 33&#x02009;mM against hCA IX and 0.8&#x02009;mM against hCA XIV<xref rid="CIT0192" ref-type="bibr"><sup>192</sup></xref>. Thus, it is unclear how robust the inhibition data is in these ITC studies when such high concentrations of CA anion inhibitors are being used.</p><p>In the subsequent papers from Matulis&#x02019; group<xref rid="CIT0193" ref-type="bibr"><sup>193&#x02013;198</sup></xref>, all of which were inspired by the tail approach (see above), reported by us, a combination of several CA inhibition assays were performed, including the FTSA method<xref rid="CIT0190" ref-type="bibr"><sup>190</sup></xref> and the ITC assay mentioned above, in addition to the stopped flow assay, which members of the Matulis group learned in 2014 in Florence at the request of Matulis (and we accepted them and taught them the CO<sub>2</sub> hydrase assay developed originally by Khalifah<xref rid="CIT0199" ref-type="bibr"><sup>199</sup></xref> which has been used in Florence since 2001). Notably, the stopped flow assay uses nanomolar concentrations of CA in the system and buffers such as Hepes or Tris at 10&#x02013;20&#x02009;mM (which do not interfere with the metal ion), phenol red (at a concentration of 0.2&#x02009;mM as an indicator) as well as low concentrations of salts to maintain a constant ionic strength (typically 20&#x02009;mM NaClO<sub>4</sub>, which is not inhibitory to most CAs<xref rid="CIT0026" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="CIT0192" ref-type="bibr"><sup>192</sup></xref>) Needless to say, all the methods used by Matulis gave very different results, and it is often difficult to understand which of them should be considered for evaluating the inhibitors from his laboratory.</p><p>Thus, the next step of Matulis&#x02019; research was to investigate the so called &#x0201c;intrinsic&#x0201d; parameters for characterising the binding of inhibitors to various CA isoforms (there is a series of 24 papers in which &#x0201c;intrinsic&#x0201d; is the keyword, repeated with great insistence, but we will consider only the one in which the method is presented in detail<xref rid="CIT0200" ref-type="bibr"><sup>200</sup></xref>) The main issue with the measurements of CA inhibition from all other laboratories around the world and in all historical periods, is according to Matulis that &#x0201c;many protein-ligand binding reactions are linked to protonation/deprotonation reactions or various conformational changes&#x0201d;, which were not considered by other researchers. N.b., conformational changes are not considered in this &#x0201c;intrinsic&#x0201d; parameter model either. Thus, the measurement of the energetic contributions for enzyme-inhibitor complex formation is considered to be correct only by considering additional contributions such as protonation/deprotonation reactions of the ligand and the protein. In this way, the observed parameter (e.g. K<sub>I</sub>, &#x00394;H, &#x00394;G, etc.) must be &#x0201c;corrected&#x0201d; to obtain the &#x0201c;intrinsic&#x0201d; value (K<sub>I</sub><sup>in</sup>) by dividing the observed parameter (K<sub>I</sub><sup>obs</sup>) by the product of the fraction of deprotonated sulphonamide (f<sub>sulf</sub>) and the fraction of enzyme in the protonated form (f<sub>CA</sub>)<xref rid="CIT0201" ref-type="bibr"><sup>201</sup></xref>. In other words, K<sub>I</sub><sup>in</sup> = K<sub>I</sub><sup>obs</sup>/(f<sub>sulf</sub> x f<sub>CA</sub>). The theoretical considerations for this &#x0201c;correction&#x0201d; of the observed K<sub>I</sub> values are based on an old but correct work from Khalifah&#x02019;s group<xref rid="CIT0202" ref-type="bibr"><sup>202</sup></xref> in which the binding of imidazole and related compounds to hCA I was investigated. Based on this work Matulis proposes the &#x0201c;intrinsic&#x0201d; parameter model considering that &#x0201c;only the deprotonated form of the sulphonamide binds to the CA active site, and that, the Zn-coordinated hydroxide must be protonated before it can be replaced by the amino group of the sulphonamide&#x0201d;. He cites the above-mentioned Khalifah paper<xref rid="CIT0202" ref-type="bibr"><sup>202</sup></xref> (based on data for imidazole, which binds in neutral form to the enzyme and does not interact with the metal ion or the water/hydroxide coordinated to the metal ion<xref rid="CIT0202" ref-type="bibr"><sup>202</sup></xref>) to justify his model for sulphonamides, which is erroneous for several reasons which we will detail here:<list list-type="roman-lower"><list-item><p>Apart the deprotonation of the sulphonamide moiety of the inhibitor and the protonation of the zinc hydroxide species of the enzyme, no hydrogen-bonding or hydrophobic interactions are considered at all in the &#x0201c;intrinsic&#x0201d; model. The Khalifah hypothesis<xref rid="CIT0202" ref-type="bibr"><sup>202</sup></xref>, which is outdated, was appropriate for investigating imidazole and related azoles as CAIs but was never applied to sulphonamides. In fact, in a very important study from Klebe and Cavalli&#x02019;s groups<xref rid="CIT0203" ref-type="bibr"><sup>203</sup></xref> it has been demonstrated by using ITC, X-ray crystallography and molecular dynamics (MD) simulations that hydrophobicity is the key factor for the binding kinetics of sulphonamide inhibitors to this enzyme. In fact, by combining the three techniques mentioned above, Klebe and Cavalli&#x02019;s groups<xref rid="CIT0203" ref-type="bibr"><sup>203</sup></xref> showed that the protein-sulphonamide association rate (k<sub>on</sub>) dramatically increases with the hydrophobicity of the inhibitor, thus demonstrating the existence of a pre-binding stage in which the enzyme-inhibitor adduct is stabilised by the hydrophobic half of the CA active site<xref rid="CIT0204" ref-type="bibr"><sup>204</sup></xref>. Such hydrophobic interactions are the only ones occurring in the so called &#x0201c;F conformation&#x0201d; of the sulphonamide inhibitor adduct, which in its neutral form (RSO<sub>2</sub>NH<sub>2</sub>) makes a hydrogen bond to the zinc-coordinated water, which is similar to the phenols or polyamines binding to the enzyme by the zinc-anchoring mechanism discussed above<xref rid="CIT0128" ref-type="bibr"><sup>128</sup></xref>. Then the &#x0201c;S state&#x0201d; emerges, which is characterised by geometries that allow hydrogen bonding of the still neutral SO<sub>2</sub>NH<sub>2</sub> moiety of the inhibitor with Thr199, Thr200, and finally the Zn<sup>2+</sup>-bound hydroxyl ion (not to zinc-water as in the Matulis model). Thus, the sulphonamide approaches hCA II in its neutral state (not deprotonated as in the Matulis model), binds to the hydrophobic patch, and in the end interacts with the Zn<sup>2+</sup> ion, being deprotonated nearby it, before finally coordinating to the zinc but only if the distance between the terminal NH and the zinc ion is within about 2.50&#x02009;&#x02212;&#x02009;2.75 &#x000c5;, i.e. the final thermodynamic minimum<xref rid="CIT0203" ref-type="bibr"><sup>203</sup></xref>. These highly relevant data, which are in total contrast with the entire Matulis &#x0201c;intrinsic&#x0201d; theory, were thereafter validated by interesting work from the groups of Klebe<xref rid="CIT0205" ref-type="bibr"><sup>205</sup></xref><sup>,</sup><xref rid="CIT0206" ref-type="bibr"><sup>206</sup></xref> and Whitesides<xref rid="CIT0207" ref-type="bibr"><sup>207&#x02013;209</sup></xref>, and are supported by our analysis of the hydrophobicity of the CA active site<xref rid="CIT0204" ref-type="bibr"><sup>204</sup></xref> as well as the report of several classes of inhibitors which anchor to zinc-bound hydroxide/water molecule<xref rid="CIT0128" ref-type="bibr"><sup>128</sup></xref>. Whitesides&#x02019; group elegantly demonstrated using ITC, crystallography and MD that the differences in binding between homologous sulphonamide ligands stem from changes in the number and organisation of active site localised water molecules rather than (or perhaps in addition to) the release of structured water from the apposed hydrophobic surfaces<xref rid="CIT0207" ref-type="bibr"><sup>207</sup></xref>. Again, the hydrophobic effects, not at all considered in the Matulis intrinsic model, are the main players in the inhibition process. In a subsequent study<xref rid="CIT0210" ref-type="bibr"><sup>210</sup></xref> again from the very famous laboratory of Whitesides, it was demonstrated that hydrophobicity is essential also for the binding of anion inhibitors (never investigated by Matulis). It was shown that the binding of the Hofmeister anions is determined by where, and how strongly, they associate with concavities on the surfaces of proteins and how, upon binding, they alter the structure of water within those hydrophobic concavities. It should be stressed here again that in the &#x0201c;intrinsic&#x0201d; method of Matulis, the measurements are done in 50&#x02009;mM phosphate buffer and 100&#x02009;mM NaCl, and that these anions are both inhibitory to CAs<xref rid="CIT0026" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="CIT0192" ref-type="bibr"><sup>192</sup></xref>, as detailed above, because they bind the zinc ion sometimes with a rather relevant affinity, but this phenomenon is never considered properly, and leads to erroneous measurements (apart from the conceptually wrong model used, see above and below).</p></list-item><list-item><p>Matulis considers that sulphonamides bind to the zinc ion in the CA active site with the sulphonamide group in the deprotonated, negatively charged form, to the water bound form (the so-called acidic form) of the enzyme, which as shown above, is not correct. Although noting that the association rates of sulphonamides to CA are slow, he considers this as &#x0201c;unexpected&#x0201d; considering that association is driven by a strong electrostatic interaction between the negatively charged sulphonamide and the positively charged Zn<sup>2+</sup>. Again, only electrostatic and acid-base equilibria are considered and not any hydrogen bonding and/or hydrophobic contacts, which are as important (or maybe even more important) than the electrostatic interactions in this context. This leads to the discovery of supposedly &#x0201c;kinetic &#x02013; selective CAIs&#x0201d; <xref rid="CIT0211" ref-type="bibr"><sup>211</sup></xref>. For decades, the kinetics of association (k<sub>on</sub>) and dissociation (k<sub>off</sub>) of the sulphonamide inhibitors to hCA II were well known<xref rid="CIT0212" ref-type="bibr"><sup>212</sup></xref><sup>,</sup><xref rid="CIT0213" ref-type="bibr"><sup>213</sup></xref>. Maren and his group reported the kinetic values for more than 25 sulphonamides directly by measurement of association rate constants (k<sub>on</sub>) and equilibrium constants (K<sub>I</sub>), which were used to measure the dissociation rate constants, k<sub>off</sub><xref rid="CIT0212" ref-type="bibr"><sup>212</sup></xref><sup>,</sup><xref rid="CIT0213" ref-type="bibr"><sup>213</sup></xref><sub>.</sub> The values for k<sub>on</sub> ranged from 0.003 to 31 x 10<sup>6</sup> L<sup>&#x02212;1</sup> M<sup>&#x02212;1</sup>, whereas the k<sub>off</sub> range was exceedingly low, 0.01&#x02013;0.05&#x02009;s<sup>&#x02212;1</sup>. Thus, the inhibitory activity was entirely influenced by the association rate k<sub>on</sub> as also detailed by the groups of Klebe, Cavalli and Whitesides<xref rid="CIT0203" ref-type="bibr"><sup>203&#x02013;210</sup></xref>, which depends primarily on hydrophobic effects. That is, another major error in the analysis of Matulis and colleagues is the lack of considering the hydrophobic effects when analysing the kinetics of association of the sulphonamide inhibitor within the active site. By analysing such low dissociation rates, they reported several ligands to be &#x0201c;kinetic-selective&#x0201d; against certain CA isozymes<xref rid="CIT0211" ref-type="bibr"><sup>211</sup></xref>. Such a proposal is completely at odds with the well-established selectivity of CAIs for 15 CA isoforms from vertebrate organisms that is based on extensive thermodynamic measurements by groups from all over the world. Will the inhibitors reach the thermodynamic equilibrium, or will they &#x0201c;hurry up&#x0201d; to selectively inhibit some isoforms for which the association rates are faster, and in this way provide novel therapeutic applications, as suggested<xref rid="CIT0211" ref-type="bibr"><sup>211</sup></xref>? We leave the answer to this question to the reader.</p></list-item><list-item><p>Matulis suggested that the observed experimental inhibition constants should not be directly translated into a structure&#x02009;&#x02212;&#x02009;activity relationship as done by all medicinal chemists, instead proposing that the observed gain in inhibitor potency might be attributed to an increase in p<italic>K</italic><sub>a</sub> for the ionisable pharmacophore (presumably deprotonation of the sulphonamide moiety, the only pharmacophore that he has explored) and a corresponding &#x0201c;jump&#x0201d; in the observed affinity instead of to an improvement in ligand-protein interactions. Based on such a model, the explanation he gave for the difference in inhibition between CF<sub>3</sub>SO<sub>2</sub>NH<sub>2</sub> (a very potent CAI, K<sub>I</sub> of 2&#x02009;nM against hCA II, as measured by Maren&#x02019;s group and confirmed by others<xref rid="CIT0213" ref-type="bibr"><sup>213</sup></xref>) and CH<sub>3</sub>SO<sub>2</sub>NH<sub>2</sub> (a very weak CAI, K<sub>I</sub> of 0.1&#x02009;mM against hCA II, again data from Maren and confirmed by other groups<xref rid="CIT0213" ref-type="bibr"><sup>213</sup></xref>) is dubious. Matulis predicts a 6-fold difference in the K<sub>I</sub> values between the two sulphonamides based on this theory, whereas the actual measured difference is 5 orders of magnitude. Thus, according to Matulis, only the quantification of intrinsic parameters may allow for the correct understanding of the inhibition mechanism. However, this method has another major issue: it works only with aromatic/heterocyclic primary sulphonamides (the data on aliphatic sulphonamides is illustrated above). All other inhibitor classes (and even a cyclic sulphonamide such as saccharin<xref rid="CIT0214" ref-type="bibr"><sup>214</sup></xref>) cannot be measured with this approach (personal communication from Matulis to CTS). In fact, there are no studies from his group on other types of inhibitors apart primary sulphonamides. As showed here, there is a large variety of other chemotypes with potent CA inhibitory action, and their inhibition effects can be measured and compared well with the sulphonamides by using the stopped-flow CO<sub>2</sub> hydrase assay queried by Liljas and referred to by Matulis. Note that other groups (Klebe, Whitesides, etc.) which use ITC and other techniques, have not queried the measurements done in our laboratory. So, what is the real problem?</p></list-item></list></p><p>Although we collaborated in the past with Matulis, his behaviour towards some of us should be discussed here. In 2013 at a conference organised by De Simone and one of us (CTS) in Naples, Italy, Matulis was invited as speaker and presented the ITC inhibition method. CTS asked whether the high concentration of sulphonate dye and the sulphonamide inhibitor will all compete for the same binding site and asked whether these effects were considered? There was not an adequate reply from Matulis. Later, during that conference, another author of this paper (RZ) was approached by Matulis who asked him to send him all his compounds that had been tested in Florence, so that he can check if the inhibition data were correct. RZ was shocked by the request and did not send the compounds to his group in Vilnius. The next year, in 2014, as already mentioned here, Matulis asked CTS to host some of his group members in Florence in order to learn the stopped flow assay. CTS agreed, and two students from Matulis&#x02019; group spent several months in Florence and learned the assay. In early 2015 after their stopped flow assay was working in Vilnius, Matulis wrote an e-mail to RZ asking him to no longer collaborate with the Florence group because &#x0201c;they do the stopped-flow measurements in an incorrect manner&#x0201d;. RZ replied to Matulis copying CTS and indicated his refusal to collaborate. Only at that point, considering this unethical behaviour, CTS decided to stop any interaction with this colleague.</p><p>Returning to the Jonsson and Liljas polemic<xref rid="CIT0178" ref-type="bibr"><sup>178</sup></xref>, although these two colleagues have not made contributions to anticancer drugs or drug design, they questioned the drug candidate, SLC-0111, which is in Phase Ib/II clinical trials for the treatment of advanced, metastatic solid tumours<xref rid="CIT0215" ref-type="bibr"><sup>215</sup></xref>. Jonsson and Liljas state that &#x0201c;it is doubtful that SLC-0111 has the required K<sub>I</sub> to advance to clinical trials&#x0201d; and that the &#x0201c;commercial interests of pharmaceutical companies and patients may be hurt&#x0201d; <xref rid="CIT0178" ref-type="bibr"><sup>178</sup></xref>, although the paper in which we describe the compound<xref rid="CIT0072" ref-type="bibr"><sup>72</sup></xref> is not correctly cited and there are no new data on this compound in their commentary. SLC-0111 was reported by the Supuran group<xref rid="CIT0072" ref-type="bibr"><sup>72</sup></xref> in efforts that spanned many years during which thousands of compounds were synthesised, assayed and characterised by X-ray crystallography and other biophysical techniques. SLC-0111 belongs to a class of ureidobenzene sulphonamides which were also assessed for their &#x0201c;druggability&#x0201d; criteria, including ADME (Absorption, Distribution, Metabolism, Excretion). Extensive <italic>in&#x000a0;vitro</italic> and <italic>in&#x000a0;vivo</italic> analysis in appropriate cancer models were then performed in Florence and other laboratories. Although the targets of this compound, CA IX/CA XII, are highly expressed within the hypoxic niches of solid tumours that represents potentially a minor portion of the total tumour cell population, these hypoxic cells have the properties for self-renewal<xref rid="CIT0216" ref-type="bibr"><sup>216&#x02013;218</sup></xref>, migration/invasion<xref rid="CIT0219" ref-type="bibr"><sup>219&#x02013;221</sup></xref>, survival in acidic tumour microenvironment<xref rid="CIT0222" ref-type="bibr"><sup>222&#x02013;227</sup></xref>, and significantly contribute to resistance to chemo-, radio-, and immune-therapies<xref rid="CIT0228" ref-type="bibr"><sup>228&#x02013;236</sup></xref>. The combination of SLC-0111 and other CAIs with chemotherapy agents<xref rid="CIT0237" ref-type="bibr"><sup>237&#x02013;239</sup></xref>, immunotherapy<xref rid="CIT0240" ref-type="bibr"><sup>240&#x02013;242</sup></xref> and radiotherapy<xref rid="CIT0243" ref-type="bibr"><sup>243</sup></xref><sup>,</sup><xref rid="CIT0244" ref-type="bibr"><sup>244</sup></xref> has been investigated, including SLC-0111, in combination with proton pump inhibitors<xref rid="CIT0236" ref-type="bibr"><sup>236</sup></xref>, antimetabolites<xref rid="CIT0237" ref-type="bibr"><sup>237</sup></xref>, cisplatin<xref rid="CIT0238" ref-type="bibr"><sup>238</sup></xref>, APE1-Ref-1 inhibitors<xref rid="CIT0239" ref-type="bibr"><sup>239</sup></xref> and histone deacetylase inhibitors<xref rid="CIT0240" ref-type="bibr"><sup>240</sup></xref>, which resulted in excellent synergistic antitumor/antimetastatic effects. Such studies showed a synergistic effect between the CAI and the second antitumor agent, but also the lack of endothelial toxicity<xref rid="CIT0241" ref-type="bibr"><sup>241</sup></xref>, which are highly important and desirable features for a sustained therapeutic response. The extensive studies reported in these and other papers, provided solid positive pre-clinical data to warrant the initiation of Phase 1 clinical trials in 2014, of which a Phase 1 safety trial with SLC-0111 (as a monotherapeutic agent), has been completed<xref rid="CIT0215" ref-type="bibr"><sup>215</sup></xref> and a Phase 1&#x02009;b trial is currently underway to evaluate SLC-0111 in combination with gemcitabine in metastatic pancreatic cancer patients whose tumours are CA IX positive (ClinicalTrials.gov Identifier: NCT03450018).</p><p>Other groups also used SLC-0111 in various biomedical studies in which selective inhibition of some CA isoforms was needed. These include the effects on prostate cancer cells of SLC-0111 alone or in combination with daunorubicin<xref rid="CIT0242" ref-type="bibr"><sup>242</sup></xref>, radiobiological effects of CA IX inhibition in human breast cancer cells<xref rid="CIT0243" ref-type="bibr"><sup>243</sup></xref>, microvascular endothelial cell pH regulation<xref rid="CIT0244" ref-type="bibr"><sup>244</sup></xref>, glycolysis and migration suppression in pulmonary microvascular endothelial cells<xref rid="CIT0245" ref-type="bibr"><sup>245</sup></xref><sup>,</sup><xref rid="CIT0246" ref-type="bibr"><sup>246</sup></xref>, involvement of CA isoforms in mitochondrial biogenesis and in the control of lactate production in human Sertoli cells<xref rid="CIT0246" ref-type="bibr"><sup>246</sup></xref>. Very recently, SLC-0111 was combined with 3-O-acetylbetulin for the treatment of CA IX-positive tumours by Vordermark&#x02019;s group, again with excellent synergistic effects<xref rid="CIT0247" ref-type="bibr"><sup>247</sup></xref>. Dedhar&#x02019;s group recently reported the interconnection between CA IX inhibition and the amino acid and acid/base transporters in hypoxic tumours<xref rid="CIT0248" ref-type="bibr"><sup>248</sup></xref> as well as the possibility to overcome the adaptive resistance to KRAS and MEK inhibitors by using such anticancer agents in combination with SLC-0111<xref rid="CIT0249" ref-type="bibr"><sup>249</sup></xref>. All these studies confirmed the usefulness of this clinical candidate, SLC-0111, in tumours and other biomedical conditions. Although Jonsson and Liljas presumably read our reply<xref rid="CIT0180" ref-type="bibr"><sup>180</sup></xref>, in their reply to our reply they continue that they, &#x0201c;would have liked to see a properly reported inhibition study of this compound to make it obvious that it indeed is a good enough inhibitor to enter Phase I/Phase II studies&#x0201d;<xref rid="CIT0181" ref-type="bibr"><sup>181</sup></xref>.</p><p>Thus, the CA field seems to be now in a typical ancient Greek tragedy situation: we have the <italic>Deus ex machina</italic> (the couple Jonsson and Liljas) who decide who is doing good and who is doing bad experiments (without however having any documented expertise in enzyme inhibition measurements) and then we have the <italic>Computantis</italic> (accountant, Matulis) who needs to check the measurements from other laboratories, and asking (in the rare occasions when he acted as reviewer to our papers) for a huge amount of supporting information data that are without any usefulness to anybody. Is this dogmatism or science?</p></sec></body><back><sec id="S0008" disp-level="1" sec-type="COI-statement"><title>Disclosure statement</title><p>All authors declare no conflict of interest except FC and CTS who are among the discoverers of SC-0111.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Meldrum</surname>
<given-names>NU</given-names></string-name>, <string-name><surname>Roughton</surname>
<given-names>FJ.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase. Its preparation and properties</article-title>. <source>J Physiol</source>
<year>1933</year>;<volume>80</volume>:<fpage>113</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">16994489</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maren</surname>
<given-names>TH.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase: chemistry, physiology, and inhibition</article-title>. <source>Physiol Rev</source>
<year>1967</year>;<volume>47</volume>:<fpage>595</fpage>&#x02013;<lpage>781</lpage>.<pub-id pub-id-type="pmid">4964060</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lindskog</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Malmstrom</surname>
<given-names>BG.</given-names></string-name></person-group>
<article-title>Metal binding and catalytic activity in bovine carbonic anhydrase</article-title>. <source>J Biol Chem</source>
<year>1962</year>;<volume>237</volume>:<fpage>1129</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="pmid">14465547</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lindskog</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Coleman</surname>
<given-names>JE.</given-names></string-name></person-group>
<article-title>The catalytic mechanism of carbonic anhydrase</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>1973</year>;<volume>70</volume>:<fpage>2505</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">4200327</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thorslund</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lindskog</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>Studies of the esterase activity and the anion inhibition of bovine zinc and cobalt carbonic anhydrases</article-title>. <source>Eur J Biochem</source>
<year>1967</year>;<volume>3</volume>:<fpage>117</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">4965793</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Strandberg</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Tilander</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Fridborg</surname>
<given-names>K</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The crystallization and x-ray investigation of one form of human carbonic anhydrase</article-title>. <source>J Mol Biol</source>
<year>1962</year>;<volume>5</volume>:<fpage>583</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">13984531</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liljas</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kannan</surname>
<given-names>KK</given-names></string-name>, <string-name><surname>Bergst&#x000e9;n</surname>
<given-names>PC</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Crystal structure of human carbonic anhydrase C</article-title>. <source>Nat New Biol</source>
<year>1972</year>;<volume>235</volume>:<fpage>131</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">4621826</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Keilin</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Mann</surname>
<given-names>T.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase. Purification and nature of the enzyme</article-title>. <source>Biochem J</source>
<year>1940</year>;<volume>34</volume>:<fpage>1163</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">16747299</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Krebs</surname>
<given-names>HA.</given-names></string-name></person-group>
<article-title>Inhibition of carbonic anhydrase by sulphonamides</article-title>. <source>Biochem J</source>
<year>1948</year>;<volume>43</volume>:<fpage>525</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">16748445</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Krebs</surname>
<given-names>HA</given-names></string-name>, <string-name><surname>Roughton</surname>
<given-names>FJ.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase as a tool in studying the mechanism of reactions involving H(2)CO(3), CO(2) or HCO(3)'</article-title>. <source>Biochem J</source>
<year>1948</year>;<volume>43</volume>:<fpage>550</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">16748449</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Carbonic anhydrases: novel therapeutic applications for inhibitors and activators</article-title>. <source>Nat Rev Drug Discov</source>
<year>2008</year>;<volume>7</volume>:<fpage>168</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">18167490</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alterio</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Di Fiore</surname>
<given-names>A</given-names></string-name>, <string-name><surname>D&#x02019;Ambrosio</surname>
<given-names>K</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms?</article-title>
<source>Chem Rev</source>
<year>2012</year>;<volume>112</volume>:<fpage>4421</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">22607219</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Krishnamurthy</surname>
<given-names>VM</given-names></string-name>, <string-name><surname>Kaufman</surname>
<given-names>GK</given-names></string-name>, <string-name><surname>Urbach</surname>
<given-names>AR</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding</article-title>. <source>Chem Rev</source>
<year>2008</year>;<volume>108</volume>:<fpage>946</fpage>&#x02013;<lpage>1051</lpage>.<pub-id pub-id-type="pmid">18335973</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mishra</surname>
<given-names>CB</given-names></string-name>, <string-name><surname>Tiwari</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Progress in the development of human carbonic anhydrase&#x000a0;inhibitors and their pharmacological applications: where are we today?</article-title>
<source>Med Res Rev</source>
<year>2020</year>;<volume>40</volume>:<fpage>2485</fpage>&#x02013;<lpage>565</lpage>.<pub-id pub-id-type="pmid">32691504</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Neri</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Interfering with pH regulation in tumours as a therapeutic strategy</article-title>. <source>Nat Rev Drug Discov</source>
<year>2011</year>;<volume>10</volume>:<fpage>767</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">21921921</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal" id="CIT0016-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Structure and function of carbonic anhydrases</article-title>. <source>Biochem J</source>
<year>2016</year>;<volume>473</volume>:<fpage>2023</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">27407171</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0016-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Carbonic anhydrases and metabolism</article-title>. <source>Metabolites</source>
<year>2018</year>;<volume>8</volume>:<fpage>25</fpage>.</mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal" id="CIT0017-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Capasso</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>An overview of the alpha-, beta- and gamma-carbonic anhydrases from Bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria?</article-title>
<source>J Enzyme Inhib Med Chem</source>
<year>2015</year>;<volume>30</volume>:<fpage>325</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">24766661</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0017-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Ozensoy Guler</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Capasso</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>A magnificent enzyme superfamily: carbonic anhydrases, their purification and characterization</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2016</year>;<volume>31</volume>:<fpage>689</fpage>&#x02013;<lpage>94</lpage>. (c) <person-group person-group-type="author"><string-name><surname>Bertucci</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Moya</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Tambutt&#x000e9;</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrases in anthozoan corals-a review</article-title>. <source>Bioorg Med Chem</source>
<year>2013</year>;<volume>21</volume>:<fpage>1437</fpage>&#x02013;<lpage>50</lpage>.</mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal" id="CIT0018-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Kikutani</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Nakajima</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Nagasato</surname>
<given-names>C</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Thylakoid luminal theta-carbonic anhydrase critical for growth and photosynthesis in the marine diatom Phaeodactylum tricornutum</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2016</year>;<volume>113</volume>:<fpage>9828</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">27531955</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0018-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Jin</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Bua</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structural and biochemical characterization of novel carbonic anhydrases from <italic>Phaeodactylum tricornutum</italic></article-title>. <source>Acta Crystallogr D Struct Biol</source>
<year>2020</year>;<volume>76</volume>:<fpage>676</fpage>&#x02013;<lpage>86</lpage>. (c) <person-group person-group-type="author"><string-name><surname>Del Prete</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Bua</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Capasso</surname>
<given-names>C.</given-names></string-name></person-group>
<article-title><italic>Escherichia coli</italic> &#x003b3;-carbonic anhydrase: characterisation and effects of simple aromatic/heterocyclic sulphonamide inhibitors</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2020</year>;<volume>35</volume>:<fpage>1545</fpage>&#x02013;<lpage>54</lpage>. (d) <person-group person-group-type="author"><string-name><surname>Kaur</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Cao</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Abutaleb</surname>
<given-names>NS</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Optimization of acetazolamide-based scaffold as potent inhibitors of vancomycin-resistant enterococcus</article-title>. <source>J Med Chem</source>
<year>2020</year>;<volume>63</volume>:<fpage>9540</fpage>&#x02013;<lpage>62</lpage>.</mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal" id="CIT0019-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Xu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Feng</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Jeffrey</surname>
<given-names>PD</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structure and metal exchange in the cadmium carbonic anhydrase of marine diatoms</article-title>. <source>Nature</source>
<year>2008</year>;<volume>452</volume>:<fpage>56</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">18322527</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0019-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Cox</surname>
<given-names>EH</given-names></string-name>, <string-name><surname>McLendon</surname>
<given-names>GL</given-names></string-name>, <string-name><surname>Morel</surname>
<given-names>FM</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The active site structure of <italic>Thalassiosira weissflogii</italic> carbonic anhydrase 1</article-title>. <source>Biochemistry</source>
<year>2000</year>;<volume>39</volume>:<fpage>12128</fpage>&#x02013;<lpage>30</lpage>. (c) <person-group person-group-type="author"><string-name><surname>Alterio</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Langella</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Viparelli</surname>
<given-names>F</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structural and inhibition insights into carbonic anhydrase CDCA1 from the marine diatom <italic>Thalassiosira weissflogii</italic></article-title>. <source>Biochimie</source>
<year>2012</year>;<volume>94</volume>:<fpage>1232</fpage>&#x02013;<lpage>41</lpage>.</mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal" id="CIT0020-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Capasso</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Bacterial, fungal and protozoan carbonic anhydrases as drug targets</article-title>. <source>Expert Opin Ther Targets</source>
<year>2015</year>;<volume>19</volume>:<fpage>1689</fpage>&#x02013;<lpage>704</lpage>.<pub-id pub-id-type="pmid">26235676</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0020-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Capasso</surname>
<given-names>C.</given-names></string-name></person-group>
<article-title>The eta-class carbonic anhydrases as drug targets for antimalarial agents</article-title>. <source>Expert Opin Ther Targets</source>
<year>2015</year>;<volume>19</volume>:<fpage>551</fpage>&#x02013;<lpage>63</lpage>. (c) <person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Capasso</surname>
<given-names>C.</given-names></string-name></person-group>
<article-title>Antibacterial carbonic anhydrase inhibitors: an update on the recent literature</article-title>. <source>Expert Opin Ther Pat</source>
<year>2020</year>;<volume>30</volume>:<fpage>963</fpage>&#x02013;<lpage>82</lpage>. (d) <person-group person-group-type="author"><string-name><surname>Angeli</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Pinteala</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Maier</surname>
<given-names>SS</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Inhibition of &#x003b1;-, &#x003b2;-, &#x003b3;-, &#x003b4;-, &#x003b6;- and &#x003b7;-class carbonic anhydrases from bacteria, fungi, algae, diatoms and protozoans with famotidine</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2019</year>;<volume>34</volume>:<fpage>644</fpage>&#x02013;<lpage>50</lpage>.</mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal" id="CIT0021-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Jensen</surname>
<given-names>EL</given-names></string-name>, <string-name><surname>Clement</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Kosta</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A new widespread subclass of carbonic anhydrase in marine phytoplankton</article-title>. <source>Isme J</source>
<year>2019</year>;<volume>13</volume>:<fpage>2094</fpage>&#x02013;<lpage>106</lpage>.<pub-id pub-id-type="pmid">31024153</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0021-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Del Prete</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Nocentini</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Capasso</surname>
<given-names>C.</given-names></string-name></person-group>
<article-title>Bacterial &#x003b9;-carbonic anhydrase: a new active class of carbonic anhydrase identified in the genome of the Gram-negative bacterium <italic>Burkholderia territorii</italic></article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2020</year>;<volume>35</volume>:<fpage>1060</fpage>&#x02013;<lpage>8</lpage>. (c) <person-group person-group-type="author"><string-name><surname>Petreni</surname>
<given-names>A</given-names></string-name>, <string-name><surname>De Luca</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Scaloni</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Anion inhibition studies of the Zn(II)-bound &#x003b9;-carbonic anhydrase from the Gram-negative bacterium <italic>Burkholderia territorii</italic></article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2021</year>;<volume>36</volume>:<fpage>372</fpage>&#x02013;<lpage>6</lpage>. (d) <person-group person-group-type="author"><string-name><surname>De Luca</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Petreni</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Nocentini</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Effect of sulfonamides and their structurally related derivatives on the activity of &#x003b9; -carbonic anhydrase from <italic>Burkholderia territorii</italic></article-title>. <source>Int J Mol Sci</source>
<year>2021</year>;<volume>22</volume>:<fpage>571</fpage>.</mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal" id="CIT0022-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Tripp</surname>
<given-names>BC</given-names></string-name>, <string-name><surname>Bell</surname>
<given-names>CB</given-names>, <suffix>3rd</suffix></string-name>, <string-name><surname>Cruz</surname>
<given-names>F</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A role for iron in an ancient carbonic anhydrase</article-title>. <source>J Biol Chem</source>
<year>2004</year>;<volume>279</volume>:<fpage>6683</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">14662760</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0022-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Zimmerman</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Ferry</surname>
<given-names>JG</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Inhibition of the archaeal beta-class (Cab) and gamma-class (Cam) carbonic anhydrases</article-title>. <source>Curr Top Med Chem</source>
<year>2007</year>;<volume>7</volume>:<fpage>901</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">17504135</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal" id="CIT0023-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Del Prete</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Fisher</surname>
<given-names>GM</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery of a new family of carbonic anhydrases in the malaria pathogen <italic>Plasmodium falciparum</italic>-the &#x003b7;-carbonic anhydrases</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2014</year>;<volume>24</volume>:<fpage>4389</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">25168745</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0023-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>De Simone</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Di Fiore</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Capasso</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>The zinc coordination pattern in the &#x003b7;-carbonic anhydrase from <italic>Plasmodium falciparum</italic> is different from all other carbonic anhydrase genetic families</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2015</year>;<volume>25</volume>:<fpage>1385</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">25765908</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal" id="CIT0024-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Domsic</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Avvaru</surname>
<given-names>BS</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>CU</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Entrapment of carbon dioxide in the active site of carbonic anhydrase II</article-title>. <source>J Biol Chem</source>
<year>2008</year>;<volume>283</volume>:<fpage>30766</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">18768466</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0024-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Sj&#x000f6;blom</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Polentarutti</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Djinovic-Carugo</surname>
<given-names>K.</given-names></string-name></person-group>
<article-title>Structural study of X-ray induced activation of carbonic anhydrase</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2009</year>;<volume>106</volume>:<fpage>10609</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">19520834</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aggarwal</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Chua</surname>
<given-names>TK</given-names></string-name>, <string-name><surname>Pinard</surname>
<given-names>MA</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbon dioxide "trapped" in a &#x003b2;-carbonic anhydrase</article-title>. <source>Biochemistry</source>
<year>2015</year>;<volume>54</volume>:<fpage>6631</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">26457866</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Simone</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>(In)organic anions as carbonic anhydrase inhibitors</article-title>. <source>J Inorg Biochem</source>
<year>2012</year>;<volume>111</volume>:<fpage>117</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">22192857</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal" id="CIT0027-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Bertini</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Luchinat</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>Binding affinity of bicarboxylate ions for cobalt (II) bovine carbonic anhydrase</article-title>. <source>Bioinorg Chem</source>
<year>1978</year>;<volume>9</volume>:<fpage>93</fpage>&#x02013;<lpage>100</lpage>.<pub-id pub-id-type="pmid">100145</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0027-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Bertini</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Luchinat</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>Interaction of cobalt-bovine carbonic anhydrase with the acetate ion</article-title>. <source>Biochim Biophys Acta</source>
<year>1976</year>;<volume>452</volume>:<fpage>239</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">825144</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal" id="CIT0028-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Bertini</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Luchinat</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Pierattelli</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Vila</surname>
<given-names>AJ.</given-names></string-name></person-group>
<article-title>The interaction of acetate and formate with cobalt carbonic anhydrase. An NMR study</article-title>. <source>Eur J Biochem</source>
<year>1992</year>;<volume>208</volume>:<fpage>607</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">1396667</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0028-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Bertini</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Luchinat</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>A <sup>31</sup>P NMR study of phosphate in presence of cobalt(II)- and copper(II)- substituted bovine carbonic anhydrase B</article-title>. <source>FEBS Lett</source>
<year>1978</year>;<volume>93</volume>:<fpage>251</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">30648</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal" id="CIT0029-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Taylor</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Coleman</surname>
<given-names>JE.</given-names></string-name></person-group>
<article-title>Electron spin resonance of <sup>63</sup>Cu and <sup>65</sup>Cu carbonic anhydrases. Resolution of nitrogen ligand superhyperfine structure</article-title>. <source>J Biol Chem</source>
<year>1973</year>;<volume>248</volume>:<fpage>749</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">4346347</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0029-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Coleman</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Coleman</surname>
<given-names>RV.</given-names></string-name></person-group>
<article-title>Magnetic circular dichroism of Co (II) carbonic anhydrase</article-title>. <source>J Biol Chem</source>
<year>1972</year>;<volume>247</volume>:<fpage>4718</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">4626366</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Coleman</surname>
<given-names>JE.</given-names></string-name></person-group>
<article-title>Mechanism of action of carbonic anhydrase. Substrate, sulfonamide, and anion binding</article-title>. <source>J Biol Chem</source>
<year>1967</year>;<volume>242</volume>:<fpage>5212</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">4965135</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>West</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Pinard</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Tu</surname>
<given-names>C</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Human carbonic anhydrase II-cyanate inhibitor complex: putting the debate to rest</article-title>. <source>Acta Crystallogr F Struct Biol Commun</source>
<year>2014</year>;<volume>70</volume>:<fpage>1324</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">25286933</pub-id></mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>J&#x000f6;nsson</surname>
<given-names>BM</given-names></string-name>, <string-name><surname>H&#x000e5;kansson</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Liljas</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>The structure of human carbonic anhydrase II in complex with bromide and azide</article-title>. <source>FEBS Lett</source>
<year>1993</year>;<volume>322</volume>:<fpage>186</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">8482389</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ferraroni</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Gaspari</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Dioxygen, an unexpected carbonic anhydrase ligand</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2018</year>;<volume>33</volume>:<fpage>999</fpage>&#x02013;<lpage>1005</lpage>.<pub-id pub-id-type="pmid">29806484</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lindahl</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Svensson</surname>
<given-names>LA</given-names></string-name>, <string-name><surname>Liljas</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>Metal poison inhibition of carbonic anhydrase</article-title>. <source>Proteins</source>
<year>1993</year>;<volume>15</volume>:<fpage>177</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">8441752</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peng</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Merz</surname>
<given-names>KM</given-names>, <suffix>Jr</suffix></string-name>, <string-name><surname>Banci</surname>
<given-names>L.</given-names></string-name></person-group>
<article-title>Binding of cyanide, cyanate, and thiocyanate to human carbonic anhydrase II</article-title>. <source>Proteins</source>
<year>1993</year>;<volume>17</volume>:<fpage>203</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">8265567</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Conroy</surname>
<given-names>CW</given-names></string-name>, <string-name><surname>Maren</surname>
<given-names>TH.</given-names></string-name></person-group>
<article-title>Is cyanate a carbonic anhydrase substrate?</article-title>
<source>Proteins</source>
<year>1997</year>;<volume>27</volume>:<fpage>272</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">9061790</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maren</surname>
<given-names>TH.</given-names></string-name></person-group>
<article-title>Kinetics, equilibrium and inhibition in the Hansson histochemical procedure for carbonic anhydrase: a validation of the method</article-title>. <source>Histochem J</source>
<year>1980</year>;<volume>12</volume>:<fpage>183</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">6778843</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maren</surname>
<given-names>TH.</given-names></string-name></person-group>
<article-title>Inhibition by anions of human red cell carbonic anhydrase B: physiological and biochemical implications</article-title>. <source>Science</source>
<year>1976</year>;<volume>194</volume>:<fpage>746</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">17832543</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Briganti</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Mangani</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase catalyzes cyanamide hydration to urea: is it mimicking the physiological reaction?</article-title>
<source>J Biol Inorg Chem</source>
<year>1999</year>;<volume>4</volume>:<fpage>528</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">10550681</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Temperini</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase inhibitors. X-ray crystal studies of the carbonic anhydrase II-trithiocarbonate adduct-an inhibitor mimicking the sulfonamide and urea binding to the enzyme</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2010</year>;<volume>20</volume>:<fpage>474</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">20005709</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guerri</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Briganti</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Mechanism of cyanamide hydration catalyzed by carbonic anhydrase II suggested by cryogenic X-ray diffraction</article-title>. <source>Biochemistry</source>
<year>2000</year>;<volume>39</volume>:<fpage>12391</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">11015219</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nettles</surname>
<given-names>WL</given-names></string-name>, <string-name><surname>Song</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Farquhar</surname>
<given-names>ER</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Characterization of the Copper(II) Binding Sites in Human Carbonic Anhydrase II</article-title>. <source>Inorg Chem</source>
<year>2015</year>;<volume>54</volume>:<fpage>5671</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">26010488</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Andring</surname>
<given-names>JT</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>CU</given-names></string-name>, <string-name><surname>McKenna</surname>
<given-names>R.</given-names></string-name></person-group>
<article-title>Structure and mechanism of copper-carbonic anhydrase II: a nitrite reductase</article-title>. <source>IUCrJ</source>
<year>2020</year>;<volume>7</volume>:<fpage>287</fpage>&#x02013;<lpage>93</lpage>.</mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Sulfonamides: a patent review (2008&#x02013;2012)</article-title>. <source>Expert Opin Ther Pat</source>
<year>2012</year>;<volume>22</volume>:<fpage>747</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">22697257</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Carbon- versus sulphur-based zinc binding groups for carbonic anhydrase inhibitors?</article-title>
<source>J Enzyme Inhib Med Chem</source>
<year>2018</year>;<volume>33</volume>:<fpage>485</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">29390912</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Secondary and tertiary sulfonamides: a patent review (2008&#x02013;2012)</article-title>. <source>Expert Opin Ther Pat</source>
<year>2013</year>;<volume>23</volume>:<fpage>203</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">23148584</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eriksson</surname>
<given-names>AE</given-names></string-name>, <string-name><surname>Kylsten</surname>
<given-names>PM</given-names></string-name>, <string-name><surname>Jones</surname>
<given-names>TA</given-names></string-name>, <string-name><surname>Liljas</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>Crystallographic studies of inhibitor binding sites in human carbonic anhydrase II: a pentacoordinated binding of the SCN- ion to the zinc at high pH</article-title>. <source>Proteins</source>
<year>1988</year>;<volume>4</volume>:<fpage>283</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">3151020</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery</article-title>. <source>Expert Opin Drug Discov</source>
<year>2020</year>;<volume>15</volume>:<fpage>671</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">32208982</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase inhibition and the management of hypoxic tumors</article-title>. <source>Metabolites</source>
<year>2017</year>;<volume>7</volume>:<fpage>48</fpage>.</mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Advances in structure-based drug discovery of carbonic anhydrase inhibitors</article-title>. <source>Expert Opin Drug Discov</source>
<year>2017</year>;<volume>12</volume>:<fpage>61</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">27783541</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Diuretics with carbonic anhydrase inhibitory action: a patent and literature review (2005&#x02013;2013)</article-title>. <source>Expert Opin Ther Pat</source>
<year>2013</year>;<volume>23</volume>:<fpage>681</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">23488823</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nocentini</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery</article-title>. <source>Expert Opin Drug Discov</source>
<year>2019</year>;<volume>14</volume>:<fpage>1175</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">31436118</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas</article-title>. <source>Expert Opin Ther Pat</source>
<year>2018</year>;<volume>28</volume>:<fpage>709</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">30217119</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Carta</surname>
<given-names>F.</given-names></string-name></person-group>
<article-title>Antiobesity carbonic anhydrase inhibitors: a literature and patent review</article-title>. <source>Expert Opin Ther Pat</source>
<year>2013</year>;<volume>23</volume>:<fpage>725</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">23607332</pub-id></mixed-citation></ref><ref id="CIT0055"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases</article-title>. <source>Expert Opin Ther Pat</source>
<year>2018</year>;<volume>28</volume>:<fpage>713</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">30175635</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Altamimi</surname>
<given-names>ASA</given-names></string-name>, <string-name><surname>Carta</surname>
<given-names>F.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019</article-title>. <source>Expert Opin Ther Pat</source>
<year>2019</year>;<volume>29</volume>:<fpage>781</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">31596641</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>The management of glaucoma and macular degeneration</article-title>. <source>Expert Opin Ther Pat</source>
<year>2019</year>;<volume>29</volume>:<fpage>745</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">31566015</pub-id></mixed-citation></ref><ref id="CIT0058"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wistrand</surname>
<given-names>PJ.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase research: a clinical perspective, past and future</article-title>. <source>EXS</source>
<year>2000</year>;<volume>90</volume>:<fpage>597</fpage>&#x02013;<lpage>609</lpage>.</mixed-citation></ref><ref id="CIT0059"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maren</surname>
<given-names>TH.</given-names></string-name></person-group>
<article-title>Sulfonamides and secretion of aqueous humor</article-title>. <source>J Exp Zool</source>
<year>1997</year>;<volume>279</volume>:<fpage>490</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">9392871</pub-id></mixed-citation></ref><ref id="CIT0060"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Nicolae</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Popescu</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase inhibitors. Part 35. Synthesis of Schiff bases derived from sulfanilamide and aromatic aldehydes: the first inhibitors with equally high affinity towards cytosolic and membrane-bound isozymes</article-title>. <source>Eur J Med Chem</source>
<year>1996</year>;<volume>31</volume>:<fpage>431</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="CIT0061"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Menabuoni</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Mincione</surname>
<given-names>F</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring?</article-title>
<source>J Med Chem</source>
<year>1999</year>;<volume>42</volume>:<fpage>2641</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">10411484</pub-id></mixed-citation></ref><ref id="CIT0062"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>D'Ascenzio</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Secci</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Carradori</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>1,3-Dipolar Cycloaddition, HPLC Enantioseparation, and Docking Studies of Saccharin/Isoxazole and Saccharin/Isoxazoline Derivatives as Selective Carbonic Anhydrase IX and XII Inhibitors</article-title>. <source>J Med Chem</source>
<year>2020</year>;<volume>63</volume>:<fpage>2470</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">31972093</pub-id></mixed-citation></ref><ref id="CIT0063"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>G&#x000fc;zel</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Temperini</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Innocenti</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors. Interaction of 2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2008</year>;<volume>18</volume>:<fpage>152</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">18024029</pub-id></mixed-citation></ref><ref id="CIT0064"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Biswas</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Aggarwal</surname>
<given-names>M</given-names></string-name>, <string-name><surname>G&#x000fc;zel</surname>
<given-names>&#x000d6;</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Conformational variability of different sulfonamide inhibitors with thienyl-acetamido moieties attributes to differential binding in the active site of cytosolic human carbonic anhydrase isoforms</article-title>. <source>Bioorg Med Chem</source>
<year>2011</year>;<volume>19</volume>:<fpage>3732</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">21620713</pub-id></mixed-citation></ref><ref id="CIT0065"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wagner</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Avvaru</surname>
<given-names>BS</given-names></string-name>, <string-name><surname>Robbins</surname>
<given-names>AH</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Coumarinyl-substituted sulfonamides strongly inhibit several human carbonic anhydrase isoforms: solution and crystallographic investigations</article-title>. <source>Bioorg Med Chem</source>
<year>2010</year>;<volume>18</volume>:<fpage>4873</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">20598552</pub-id></mixed-citation></ref><ref id="CIT0066"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Avvaru</surname>
<given-names>BS</given-names></string-name>, <string-name><surname>Wagner</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Maresca</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a less utilized binding pocket than most hydrophobic inhibitors</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2010</year>;<volume>20</volume>:<fpage>4376</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">20605094</pub-id></mixed-citation></ref><ref id="CIT0067"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Garaj</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Maresca</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Sulfonamides incorporating 1,3,5-triazine moieties selectively and potently inhibit carbonic anhydrase transmembrane isoforms IX, XII and XIV over cytosolic isoforms I and II: solution and X-ray crystallographic studies</article-title>. <source>Bioorg Med Chem</source>
<year>2011</year>;<volume>19</volume>:<fpage>3105</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">21515057</pub-id></mixed-citation></ref><ref id="CIT0068"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Birkmann</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Pfaff</surname>
<given-names>T</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Lead development of thiazolylsulfonamides with carbonic anhydrase inhibitory action</article-title>. <source>J Med Chem</source>
<year>2017</year>;<volume>60</volume>:<fpage>3154</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">28272885</pub-id></mixed-citation></ref><ref id="CIT0069"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alterio</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Vitale</surname>
<given-names>RM</given-names></string-name>, <string-name><surname>Monti</surname>
<given-names>SM</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX</article-title>. <source>J Am Chem Soc</source>
<year>2006</year>;<volume>128</volume>:<fpage>8329</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">16787097</pub-id></mixed-citation></ref><ref id="CIT0070"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pacchiano</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Aggarwal</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Avvaru</surname>
<given-names>BS</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency</article-title>. <source>Chem Commun (Camb)</source>
<year>2010</year>;<volume>46</volume>:<fpage>8371</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">20922253</pub-id></mixed-citation></ref><ref id="CIT0071"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mboge</surname>
<given-names>MY</given-names></string-name>, <string-name><surname>Mahon</surname>
<given-names>BP</given-names></string-name>, <string-name><surname>Lamas</surname>
<given-names>N</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structure activity study of carbonic anhydrase IX: selective inhibition with ureido-substituted benzenesulfonamides</article-title>. <source>Eur J Med Chem</source>
<year>2017</year>;<volume>132</volume>:<fpage>184</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">28363153</pub-id></mixed-citation></ref><ref id="CIT0072"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pacchiano</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <string-name><surname>McDonald</surname>
<given-names>PC</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis</article-title>. <source>J Med Chem</source>
<year>2011</year>;<volume>54</volume>:<fpage>1896</fpage>&#x02013;<lpage>902</lpage>.<pub-id pub-id-type="pmid">21361354</pub-id></mixed-citation></ref><ref id="CIT0073"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tanpure</surname>
<given-names>RP</given-names></string-name>, <string-name><surname>Ren</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Peat</surname>
<given-names>TS</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors with dual-tail moieties to match the hydrophobic and hydrophilic halves of the carbonic anhydrase active site</article-title>. <source>J Med Chem</source>
<year>2015</year>;<volume>58</volume>:<fpage>1494</fpage>&#x02013;<lpage>501</lpage>.<pub-id pub-id-type="pmid">25581127</pub-id></mixed-citation></ref><ref id="CIT0074"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bonardi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Nocentini</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bua</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Sulfonamide inhibitors of human carbonic anhydrases designed through a three-tails approach: improving ligand/isoform matching and selectivity of action</article-title>. <source>J Med Chem</source>
<year>2020</year>;<volume>63</volume>:<fpage>7422</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">32519851</pub-id></mixed-citation></ref><ref id="CIT0075"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gieling</surname>
<given-names>RG</given-names></string-name>, <string-name><surname>Babur</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mamnani</surname>
<given-names>L</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts</article-title>. <source>J Med Chem</source>
<year>2012</year>;<volume>55</volume>:<fpage>5591</fpage>&#x02013;<lpage>600</lpage>.<pub-id pub-id-type="pmid">22621623</pub-id></mixed-citation></ref><ref id="CIT0076"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bozdag</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Ceruso</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery of 4-hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 analogues for the treatment of hypoxic tumors overexpressing carbonic anhydrase IX</article-title>. <source>J Med Chem</source>
<year>2018</year>;<volume>61</volume>:<fpage>6328</fpage>&#x02013;<lpage>38</lpage>.<pub-id pub-id-type="pmid">29962205</pub-id></mixed-citation></ref><ref id="CIT0077"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Akocak</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lolak</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Bua</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and biological evaluation of novel N,N'-diaryl cyanoguanidines acting as potent and selective carbonic anhydrase II inhibitors</article-title> . <source>Bioorg Chem</source>
<year>2018</year>;<volume>77</volume>:<fpage>245</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">29421699</pub-id></mixed-citation></ref><ref id="CIT0078"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lolak</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Akocak</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Bua</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design and synthesis of novel 1,3-diaryltriazene-substituted sulfonamides as potent and selective carbonic anhydrase II inhibitors</article-title>. <source>Bioorg Chem</source>
<year>2018</year>;<volume>77</volume>:<fpage>542</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">29462772</pub-id></mixed-citation></ref><ref id="CIT0079"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lomelino</surname>
<given-names>CL</given-names></string-name>, <string-name><surname>Mahon</surname>
<given-names>BP</given-names></string-name>, <string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Kinetic and X-ray crystallographic investigations on carbonic anhydrase isoforms I, II, IX and XII of a thioureido analog of SLC-0111</article-title>. <source>Bioorg Med Chem</source>
<year>2016</year>;<volume>24</volume>:<fpage>976</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">26810836</pub-id></mixed-citation></ref><ref id="CIT0080"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Angeli</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Tanini</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Peat</surname>
<given-names>TS</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery of new selenoureido analogues of 4-(4-Fluorophenylureido)benzenesulfonamide as Carbonic Anhydrase Inhibitors</article-title>. <source>ACS Med Chem Lett</source>
<year>2017</year>;<volume>8</volume>:<fpage>963</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">28947945</pub-id></mixed-citation></ref><ref id="CIT0081"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eldehna</surname>
<given-names>WM</given-names></string-name>, <string-name><surname>Abo-Ashour</surname>
<given-names>MF</given-names></string-name>, <string-name><surname>Berrino</surname>
<given-names>E</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>SLC-0111 enaminone analogs, 3/4-(3-aryl-3-oxopropenyl) aminobenzenesulfonamides, as novel selective subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform IX</article-title>. <source>Bioorg Chem</source>
<year>2019</year>;<volume>83</volume>:<fpage>549</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">30471577</pub-id></mixed-citation></ref><ref id="CIT0082"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Congiu</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Onnis</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Deplano</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis of sulfonamides incorporating piperazinyl-ureido moieties and their carbonic anhydrase I, II, IX and XII inhibitory activity</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2015</year>;<volume>25</volume>:<fpage>3850</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">26233435</pub-id></mixed-citation></ref><ref id="CIT0083"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moi</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Nocentini</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Deplano</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Appliance of the piperidinyl-hydrazidoureido linker to benzenesulfonamide compounds: synthesis, in&#x000a0;vitro and in silico evaluation of potent carbonic anhydrase II, IX and XII inhibitors</article-title>. <source>Bioorg Chem</source>
<year>2020</year>;<volume>98</volume>:<fpage>103728</fpage>.<pub-id pub-id-type="pmid">32182519</pub-id></mixed-citation></ref><ref id="CIT0084"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abo-Ashour</surname>
<given-names>MF</given-names></string-name>, <string-name><surname>Eldehna</surname>
<given-names>WM</given-names></string-name>, <string-name><surname>Nocentini</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel synthesized SLC-0111 thiazole and thiadiazole analogues: determination of their carbonic anhydrase inhibitory activity and molecular modeling studies</article-title>. <source>Bioorg Chem</source>
<year>2019</year>;<volume>87</volume>:<fpage>794</fpage>&#x02013;<lpage>802</lpage>.<pub-id pub-id-type="pmid">30978604</pub-id></mixed-citation></ref><ref id="CIT0085"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alkhaldi</surname>
<given-names>AAM</given-names></string-name>, <string-name><surname>Al-Sanea</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Nocentini</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>3-Methylthiazolo[3,2-a]benzimidazole-benzenesulfonamide conjugates as novel carbonic anhydrase inhibitors endowed with anticancer activity: design, synthesis, biological and molecular modeling studies</article-title>. <source>Eur J Med Chem</source>
<year>2020</year>;<volume>207</volume>:<fpage>112745</fpage>.<pub-id pub-id-type="pmid">32877804</pub-id></mixed-citation></ref><ref id="CIT0086"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Iikuni</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ono</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Watanabe</surname>
<given-names>H</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Cancer radiotheranostics targeting carbonic anhydrase-IX with <sup>111</sup>In- and <sup>90</sup>Y-labeled ureidosulfonamide scaffold for SPECT imaging and radionuclide-based therapy</article-title>. <source>Theranostics</source>
<year>2018</year>;<volume>8</volume>:<fpage>2992</fpage>&#x02013;<lpage>3006</lpage>.<pub-id pub-id-type="pmid">29896298</pub-id></mixed-citation></ref><ref id="CIT0087"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eldehna</surname>
<given-names>WM</given-names></string-name>, <string-name><surname>Fares</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ceruso</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Amido/ureidosubstituted benzenesulfonamides-isatin conjugates as low nanomolar/subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform XII</article-title>. <source>Eur J Med Chem</source>
<year>2016</year>;<volume>110</volume>:<fpage>259</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">26840366</pub-id></mixed-citation></ref><ref id="CIT0088"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eldehna</surname>
<given-names>WM</given-names></string-name>, <string-name><surname>Abo-Ashour</surname>
<given-names>MF</given-names></string-name>, <string-name><surname>Nocentini</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Enhancement of the tail hydrophobic interactions within the carbonic anhydrase IX active site via structural extension: design and synthesis of novel N-substituted isatins-SLC-0111 hybrids as carbonic anhydrase inhibitors and antitumor agents</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>;<volume>162</volume>:<fpage>147</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">30445264</pub-id></mixed-citation></ref><ref id="CIT0089"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Osman</surname>
<given-names>SM</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs</article-title>. <source>Bioorg Med Chem</source>
<year>2017</year>;<volume>25</volume>:<fpage>2569</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">28347633</pub-id></mixed-citation></ref><ref id="CIT0090"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Akgul</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Singh</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Andring</surname>
<given-names>JT</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Handling drug-target selectivity: a study on ureido containing Carbonic Anhydrase inhibitors</article-title>. <source>Eur J Med Chem</source>
<year>2020</year>;<fpage>113035</fpage>DOI:<pub-id pub-id-type="doi">10.1016/j.ejmech.2020.113035</pub-id><pub-id pub-id-type="pmid">33303238</pub-id></mixed-citation></ref><ref id="CIT0091"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nocentini</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Gratteri</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Phosphorus versus sulfur: discovery of benzenephosphonamidates as versatile sulfonamide-mimic chemotypes acting as carbonic anhydrase inhibitors</article-title>. <source>Chemistry</source>
<year>2019</year>;<volume>25</volume>:<fpage>1188</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">30411821</pub-id></mixed-citation></ref><ref id="CIT0092"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Aggarwal</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Maresca</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Dithiocarbamates: a new class of carbonic anhydrase inhibitors. Crystallographic and kinetic investigations</article-title>. <source>Chem Commun (Camb)</source>
<year>2012</year>;<volume>48</volume>:<fpage>1868</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">22218610</pub-id></mixed-citation></ref><ref id="CIT0093"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Durante</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Di Leva</surname>
<given-names>FS</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Monothiocarbamates strongly inhibit carbonic anhydrases in&#x000a0;vitro and possess intraocular pressure lowering activity in an animal model of glaucoma</article-title>. <source>J Med Chem</source>
<year>2016</year>;<volume>59</volume>:<fpage>5857</fpage>&#x02013;<lpage>67</lpage>.<pub-id pub-id-type="pmid">27253845</pub-id></mixed-citation></ref><ref id="CIT0094"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Akdemir</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Xanthates and trithiocarbonates strongly inhibit carbonic anhydrases and show antiglaucoma effects in&#x000a0;vivo</article-title>. <source>J Med Chem</source>
<year>2013</year>;<volume>56</volume>:<fpage>4691</fpage>&#x02013;<lpage>700</lpage>.<pub-id pub-id-type="pmid">23647428</pub-id></mixed-citation></ref><ref id="CIT0095"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Angeli</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Tanini</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Nocentini</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Selenols: a new class of carbonic anhydrase inhibitors</article-title>. <source>Chem Commun (Camb)</source>
<year>2019</year>;<volume>55</volume>:<fpage>648</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">30560259</pub-id></mixed-citation></ref><ref id="CIT0096"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tanini</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Capperucci</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ferraroni</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Direct and straightforward access to substituted alkyl selenols as novel carbonic anhydrase inhibitors</article-title>. <source>Eur J Med Chem</source>
<year>2020</year>;<volume>185</volume>:<fpage>111811</fpage>.<pub-id pub-id-type="pmid">31693947</pub-id></mixed-citation></ref><ref id="CIT0097"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Langella</surname>
<given-names>E</given-names></string-name>, <string-name><surname>D'Ambrosio</surname>
<given-names>K</given-names></string-name>, <string-name><surname>D'Ascenzio</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A Combined crystallographic and theoretical study explains the capability of carboxylic acids to adopt multiple binding modes in the active site of carbonic anhydrases</article-title>. <source>Chemistry</source>
<year>2016</year>;<volume>22</volume>:<fpage>97</fpage>&#x02013;<lpage>100</lpage>.<pub-id pub-id-type="pmid">26507456</pub-id></mixed-citation></ref><ref id="CIT0098"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Di Fiore</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Maresca</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Hydroxamate represents a versatile zinc binding group for the development of new carbonic anhydrase inhibitors</article-title>. <source>Chem Commun (Camb)</source>
<year>2012</year>;<volume>48</volume>:<fpage>8838</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">22836518</pub-id></mixed-citation></ref><ref id="CIT0099"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alterio</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Cadoni</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Esposito</surname>
<given-names>D</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Benzoxaborole as a new chemotype for carbonic anhydrase inhibition</article-title>. <source>Chem Commun (Camb)</source>
<year>2016</year>;<volume>52</volume>:<fpage>11983</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">27722534</pub-id></mixed-citation></ref><ref id="CIT0100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Langella</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Alterio</surname>
<given-names>V</given-names></string-name>, <string-name><surname>D'Ambrosio</surname>
<given-names>K</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Exploring benzoxaborole derivatives as carbonic anhydrase inhibitors: a structural and computational analysis reveals their conformational variability as a tool to increase enzyme selectivity</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2019</year>;<volume>34</volume>:<fpage>1498</fpage>&#x02013;<lpage>505</lpage>.<pub-id pub-id-type="pmid">31423863</pub-id></mixed-citation></ref><ref id="CIT0101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nocentini</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Winum</surname>
<given-names>JY.</given-names></string-name></person-group>
<article-title>Benzoxaborole compounds for therapeutic uses: a patent review (2010&#x02013;2018)</article-title>. <source>Expert Opin Ther Pat</source>
<year>2018</year>;<volume>28</volume>:<fpage>493</fpage>&#x02013;<lpage>504</lpage>.<pub-id pub-id-type="pmid">29727210</pub-id></mixed-citation></ref><ref id="CIT0102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Simone</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Angeli</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bozdag</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Inhibition of carbonic anhydrases by a substrate analog: benzyl carbamate directly coordinates the catalytic zinc ion mimicking bicarbonate binding</article-title>. <source>Chem Commun (Camb)</source>
<year>2018</year>;<volume>54</volume>:<fpage>10312</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">30140816</pub-id></mixed-citation></ref><ref id="CIT0103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Temperini</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Innocenti</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule</article-title>. <source>J Med Chem</source>
<year>2010</year>;<volume>53</volume>:<fpage>5511</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">20590092</pub-id></mixed-citation></ref><ref id="CIT0104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nair</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Ludwig</surname>
<given-names>PA</given-names></string-name>, <string-name><surname>Christianson</surname>
<given-names>DW.</given-names></string-name></person-group>
<article-title>Two-site binding of phenol in the active site of human carbonic anhydrase II: structural implications for substrate association</article-title>. <source>J Am Chem Soc</source>
<year>1994</year>;<volume>116</volume>:<fpage>3659</fpage>&#x02013;<lpage>60</lpage>.</mixed-citation></ref><ref id="CIT0105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Innocenti</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors: interactions of phenols with the 12 catalytically active mammalian isoforms (CA I-XIV)</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2008</year>;<volume>18</volume>:<fpage>1583</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">18242985</pub-id></mixed-citation></ref><ref id="CIT0106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Innocenti</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid</article-title>. <source>Bioorg Med Chem</source>
<year>2008</year>;<volume>16</volume>:<fpage>7424</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">18579385</pub-id></mixed-citation></ref><ref id="CIT0107"><label>107</label><mixed-citation publication-type="journal" id="CIT0107-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Bayram</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Senturk</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kufrevioglu</surname>
<given-names>OI</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II</article-title>. <source>Bioorg Med Chem</source>
<year>2008</year>;<volume>16</volume>:<fpage>9101</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">18819808</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0107-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Innocenti</surname>
<given-names>A</given-names></string-name>, <string-name><surname>G&#x000fc;l&#x000e7;in</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2010</year>;<volume>20</volume>:<fpage>5050</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">20674354</pub-id></mixed-citation></ref><ref id="CIT0108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nocentini</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bonardi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Gratteri</surname>
<given-names>P</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Steroids interfere with human carbonic anhydrase activity by using alternative binding mechanisms</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2018</year>;<volume>33</volume>:<fpage>1453</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">30221552</pub-id></mixed-citation></ref><ref id="CIT0109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Karioti</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Phenols and polyphenols as carbonic anhydrase inhibitors</article-title>. <source>Molecules</source>
<year>2016</year>;<volume>21</volume>:<fpage>1649</fpage>.</mixed-citation></ref><ref id="CIT0110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tars</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Kazaks</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Sulfocoumarins (1,2-benzoxathiine-2,2-dioxides): a class of potent and isoform-selective inhibitors of tumor-associated carbonic anhydrases</article-title>. <source>J Med Chem</source>
<year>2013</year>;<volume>56</volume>:<fpage>293</fpage>&#x02013;<lpage>300</lpage>.<pub-id pub-id-type="pmid">23241068</pub-id></mixed-citation></ref><ref id="CIT0111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grandane</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Tanc</surname>
<given-names>M</given-names></string-name>, <string-name><surname>&#x0017d;alubovskis</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Synthesis of 6-aryl-substituted sulfocoumarins and investigation of their carbonic anhydrase inhibitory action</article-title>. <source>Bioorg Med Chem</source>
<year>2015</year>;<volume>23</volume>:<fpage>1430</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">25753329</pub-id></mixed-citation></ref><ref id="CIT0112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pustenko</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Stepanovs</surname>
<given-names>D</given-names></string-name>, <string-name><surname>&#x0017d;alubovskis</surname>
<given-names>R</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>3H-1,2-benzoxathiepine 2,2-dioxides: a new class of isoform-selective carbonic anhydrase inhibitors</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2017</year>;<volume>32</volume>:<fpage>767</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">28537099</pub-id></mixed-citation></ref><ref id="CIT0113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grandane</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Nocentini</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Werner</surname>
<given-names>T</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Benzoxepinones: a new isoform-selective class of tumor associated carbonic anhydrase inhibitors</article-title>. <source>Bioorg Med Chem</source>
<year>2020</year>;<volume>28</volume>:<fpage>115496</fpage>.<pub-id pub-id-type="pmid">32327349</pub-id></mixed-citation></ref><ref id="CIT0114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ferraroni</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Thioxocoumarins show an alternative carbonic anhydrase inhibition mechanism compared to coumarins</article-title>. <source>J Med Chem</source>
<year>2016</year>;<volume>59</volume>:<fpage>462</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">26688270</pub-id></mixed-citation></ref><ref id="CIT0115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maresca</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Temperini</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Vu</surname>
<given-names>H</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors</article-title>. <source>J Am Chem Soc</source>
<year>2009</year>;<volume>131</volume>:<fpage>3057</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">19206230</pub-id></mixed-citation></ref><ref id="CIT0116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maresca</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Temperini</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Pochet</surname>
<given-names>L</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins</article-title>. <source>J Med Chem</source>
<year>2010</year>;<volume>53</volume>:<fpage>335</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">19911821</pub-id></mixed-citation></ref><ref id="CIT0117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Temperini</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Innocenti</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The coumarin-binding site in carbonic anhydrase accommodates structurally diverse inhibitors: the antiepileptic lacosamide as an example and lead molecule for novel classes of carbonic anhydrase inhibitors</article-title>. <source>J Med Chem</source>
<year>2010</year>;<volume>53</volume>:<fpage>850</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">20028100</pub-id></mixed-citation></ref><ref id="CIT0118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Coumarin carbonic anhydrase inhibitors from natural sources</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2020</year>;<volume>35</volume>:<fpage>1462</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">32779543</pub-id></mixed-citation></ref><ref id="CIT0119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Touisni</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Maresca</surname>
<given-names>A</given-names></string-name>, <string-name><surname>McDonald</surname>
<given-names>PC</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Glycosyl coumarin carbonic anhydrase IX and XII inhibitors strongly attenuate the growth of primary breast tumors</article-title>. <source>J Med Chem</source>
<year>2011</year>;<volume>54</volume>:<fpage>8271</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">22077347</pub-id></mixed-citation></ref><ref id="CIT0120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Davis</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Maresca</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Natural product coumarins that inhibit human carbonic anhydrases</article-title>. <source>Bioorg Med Chem</source>
<year>2013</year>;<volume>21</volume>:<fpage>1539</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">22892213</pub-id></mixed-citation></ref><ref id="CIT0121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Luca</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Mancuso</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Ferro</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases</article-title>. <source>Eur J Med Chem</source>
<year>2018</year>;<volume>143</volume>:<fpage>276</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">29197732</pub-id></mixed-citation></ref><ref id="CIT0122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maresca</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2010</year>;<volume>20</volume>:<fpage>7255</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">21067924</pub-id></mixed-citation></ref><ref id="CIT0123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maresca</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Coumarins incorporating hydroxy- and chloro-moieties selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2010</year>;<volume>20</volume>:<fpage>4511</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">20580555</pub-id></mixed-citation></ref><ref id="CIT0124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bonneau</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Maresca</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Winum</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Metronidazole-coumarin conjugates and 3-cyano-7-hydroxy-coumarin act as isoform-selective carbonic anhydrase inhibitors</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2013</year>;<volume>28</volume>:<fpage>397</fpage>&#x02013;<lpage>401</lpage>.<pub-id pub-id-type="pmid">22299576</pub-id></mixed-citation></ref><ref id="CIT0125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>D'Ambrosio</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Carradori</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Monti</surname>
<given-names>SM</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Out of the active site binding pocket for carbonic anhydrase inhibitors</article-title>. <source>Chem Commun (Camb)</source>
<year>2015</year>;<volume>51</volume>:<fpage>302</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">25407638</pub-id></mixed-citation></ref><ref id="CIT0126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bouzina</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Berredjem</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Nocentini</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Ninhydrins inhibit carbonic anhydrases directly binding to the metal ion</article-title>. <source>Eur J Med Chem</source>
<year>2021</year>;<volume>209</volume>:<fpage>112875</fpage>.<pub-id pub-id-type="pmid">33059188</pub-id></mixed-citation></ref><ref id="CIT0127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>D'Ambrosio</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Carradori</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Cesa</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Catechols: a new class of carbonic anhydrase inhibitors</article-title>. <source>Chem Commun (Camb)</source>
<year>2020</year>;<volume>56</volume>:<fpage>13033</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">33000794</pub-id></mixed-citation></ref><ref id="CIT0128"><label>128</label><mixed-citation publication-type="journal" id="CIT0128-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>How many carbonic anhydrase inhibition mechanisms exist?</article-title>
<source>J Enzyme Inhib Med Chem</source>
<year>2016</year>;<volume>31</volume>:<fpage>345</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">26619898</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0128-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Structure-based drug discovery of carbonic anhydrase inhibitors</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2012</year>;<volume>27</volume>:<fpage>759</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">22468747</pub-id></mixed-citation></ref><ref id="CIT0129"><label>129</label><mixed-citation publication-type="journal" id="CIT0129-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Aggarwal</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kondeti</surname>
<given-names>B</given-names></string-name>, <string-name><surname>McKenna</surname>
<given-names>R.</given-names></string-name></person-group>
<article-title>Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review</article-title>. <source>Expert Opin Ther Pat</source>
<year>2013</year>;<volume>23</volume>:<fpage>717</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="pmid">23514045</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0129-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Thiry</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Dogn&#x000e9;</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Masereel</surname>
<given-names>B.</given-names></string-name></person-group>
<article-title>Anticonvulsant sulfonamides/sulfamates/sulfamides with carbonic anhydrase inhibitory activity: drug design and mechanism of action</article-title>. <source>Curr Pharm Des</source>
<year>2008</year>;<volume>14</volume>:<fpage>661</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">18336312</pub-id></mixed-citation></ref><ref id="CIT0130"><label>130</label><mixed-citation publication-type="journal" id="CIT0130-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Hen</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Bialer</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Yagen</surname>
<given-names>B</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII, and XIV</article-title>. <source>J Med Chem</source>
<year>2011</year>;<volume>54</volume>:<fpage>3977</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">21506569</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0130-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Thiry</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Dogn&#x000e9;</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Masereel</surname>
<given-names>B.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase inhibitors as anticonvulsant agents</article-title>. <source>Curr Top Med Chem</source>
<year>2007</year>;<volume>7</volume>:<fpage>855</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">17504130</pub-id></mixed-citation></ref><ref id="CIT0131"><label>131</label><mixed-citation publication-type="journal" id="CIT0131-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Mu&#x000f1;oz</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Lamm</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Poppers</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Lamm</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>Acetazolamide promotes decreased consumption of carbonated drinks and weight loss</article-title>. <source>Oxf Med Case Reports</source>
<year>2018</year>;<volume>2018</volume>:<fpage>omy081</fpage>.<pub-id pub-id-type="pmid">30397500</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0131-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Bejaoui</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Pantazi</surname>
<given-names>E</given-names></string-name>, <string-name><surname>De Luca</surname>
<given-names>V</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Acetazolamide protects steatotic liver grafts against cold ischemia reperfusion injury</article-title>. <source>J Pharmacol Exp Ther</source>
<year>2015</year>;<volume>355</volume>:<fpage>191</fpage>&#x02013;<lpage>8</lpage>. (c) <person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity</article-title>. <source>Expert Opin Emerg Drugs</source>
<year>2012</year>;<volume>17</volume>:<fpage>11</fpage>&#x02013;<lpage>5</lpage>. (d) <person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Di Fiore</surname>
<given-names>A</given-names></string-name>, <string-name><surname>De Simone</surname>
<given-names>G.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity</article-title>. <source>Expert Opin Emerg Drugs</source>
<year>2008</year>;<volume>13</volume>:<fpage>383</fpage>&#x02013;<lpage>92</lpage>.</mixed-citation></ref><ref id="CIT0132"><label>132</label><mixed-citation publication-type="journal" id="CIT0132-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Costa</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Ambrosio</surname>
<given-names>FA</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A computer-assisted discovery of novel potential anti-obesity compounds as selective carbonic anhydrase VA inhibitors</article-title>. <source>Eur J Med Chem</source>
<year>2019</year>;<volume>181</volume>:<fpage>111565</fpage>.<pub-id pub-id-type="pmid">31387062</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0132-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Costa</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Gidaro</surname>
<given-names>MC</given-names></string-name>, <string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>al. Active components of essential oils as anti-obesity potential drugs investigated by in silico techniques</article-title>. <source>J Agric Food Chem</source>
<year>2016</year>;<volume>64</volume>:<fpage>5295</fpage>&#x02013;<lpage>300</lpage>. (c) <person-group person-group-type="author"><string-name><surname>Arechederra</surname>
<given-names>RL</given-names></string-name>, <string-name><surname>Waheed</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Sly</surname>
<given-names>WS</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>al. Effect of sulfonamides as carbonic anhydrase VA and VB inhibitors on mitochondrial metabolic energy conversion</article-title>. <source>Bioorg Med Chem</source>
<year>2013</year>;<volume>21</volume>:<fpage>1544</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="CIT0133"><label>133</label><mixed-citation publication-type="journal" id="CIT0133-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>For the treatment of idiopathic intracranial hypertension</article-title>. <source>Expert Rev Neurother</source>. <year>2015</year>;<volume>15</volume>:<fpage>851</fpage>&#x02013;<lpage>856</lpage>;<pub-id pub-id-type="pmid">26154918</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0133-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors</article-title>. <source>Expert Opin Drug Metab Toxicol</source>
<year>2016</year>;<volume>12</volume>:<fpage>423</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">26878088</pub-id></mixed-citation></ref><ref id="CIT0134"><label>134</label><mixed-citation publication-type="journal">a)<person-group person-group-type="author"><string-name><surname>Di Cesare Mannelli</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Micheli</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibition for the management of cerebral ischemia: in&#x000a0;vivo evaluation of sulfonamide and coumarin inhibitors</article-title>. <source>Enzyme Inhib Med Chem</source>
<year>2016</year>;<volume>31</volume>:<fpage>894</fpage>&#x02013;<lpage>9</lpage>. (b) <person-group person-group-type="author"><string-name><surname>Angeli</surname>
<given-names>A</given-names></string-name>, <string-name><surname>di Cesare Mannelli</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Trallori</surname>
<given-names>E</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design, synthesis, and X-ray of selenides as new class of agents for prevention of diabetic cerebrovascular pathology</article-title>. <source>ACS Med Chem Lett</source>
<year>2018</year>;<volume>9</volume>:<fpage>462</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="CIT0135"><label>135</label><mixed-citation publication-type="journal" id="CIT0135-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Di Cesare Mannelli</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Pinard</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects</article-title>. <source>Bioorg Med Chem</source>
<year>2015</year>;<volume>23</volume>:<fpage>1828</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">25766630</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0135-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Voipio</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Innocenti</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2005</year>;<volume>15</volume>:<fpage>971</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">15686895</pub-id></mixed-citation></ref><ref id="CIT0136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase inhibition and the management of neuropathic pain</article-title>. <source>Expert Rev Neurother</source>
<year>2016</year>;<volume>16</volume>:<fpage>961</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">27211329</pub-id></mixed-citation></ref><ref id="CIT0137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Margheri</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Ceruso</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Overexpression of the transmembrane carbonic anhydrase isoforms IX and XII in the inflamed synovium</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2016</year>;<volume>31</volume>:<fpage>60</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">27539792</pub-id></mixed-citation></ref><ref id="CIT0138"><label>138</label><mixed-citation publication-type="journal" id="CIT0138-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Bua</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Di Cesare Mannelli</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the treatment of rheumatoid arthritis</article-title>. <source>J Med Chem</source>
<year>2017</year>;<volume>60</volume>:<fpage>1159</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">28075587</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0138-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Bua</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lucarini</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Micheli</surname>
<given-names>L</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Bioisosteric development of multitarget nonsteroidal anti-inflammatory drug-carbonic anhydrases inhibitor hybrids for the management of rheumatoid arthritis</article-title>. <source>J Med Chem</source>
<year>2020</year>;<volume>63</volume>:<fpage>2325</fpage>&#x02013;<lpage>42</lpage>. (c) <person-group person-group-type="author"><string-name><surname>Akgul</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Di Cesare Mannelli</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs-CAIs) for the management of rheumatoid arthritis</article-title>. <source>J Med Chem</source>
<year>2018</year>;<volume>61</volume>:<fpage>4961</fpage>&#x02013;<lpage>77</lpage>.</mixed-citation></ref><ref id="CIT0139"><label>139</label><mixed-citation publication-type="journal" id="CIT0139-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Micheli</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Bozdag</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Akgul</surname>
<given-names>O</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Pain relieving effect of-NSAIDs-CAIs hybrid molecules: systemic and intra-articular treatments against rheumatoid arthritis</article-title>. <source>Int J Mol Sci</source>
<year>2019</year>;<volume>20</volume>:<fpage>1923</fpage>.</mixed-citation><mixed-citation publication-type="journal" id="CIT0139-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Lucarini</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Durante</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Sgambellone</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Effects of new NSAID-CAI hybrid compounds in inflammation and lung fibrosis</article-title>. <source>Biomolecules</source>
<year>2020</year>;<volume>10</volume>:<fpage>1307</fpage>.</mixed-citation></ref><ref id="CIT0140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Berrino</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Milazzo</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Micheli</surname>
<given-names>L</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and evaluation of carbonic anhydrase inhibitors with carbon monoxide releasing properties for the management of rheumatoid arthritis</article-title>. <source>J Med Chem</source>
<year>2019</year>;<volume>62</volume>:<fpage>7233</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">31287314</pub-id></mixed-citation></ref><ref id="CIT0141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pastorek</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Pastorekov&#x000e1;</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Callebaut</surname>
<given-names>I</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment</article-title>. <source>Oncogene</source>
<year>1994</year>;<volume>9</volume>:<fpage>2877</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">8084592</pub-id></mixed-citation></ref><ref id="CIT0142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>T&#x000fc;reci</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Sahin</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Vollmar</surname>
<given-names>E</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>1998</year>;<volume>95</volume>:<fpage>7608</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">9636197</pub-id></mixed-citation></ref><ref id="CIT0143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Svastov&#x000e1;</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Hul&#x000ed;kov&#x000e1;</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Rafajov&#x000e1;</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH</article-title>. <source>FEBS Lett</source>
<year>2004</year>;<volume>577</volume>:<fpage>439</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">15556624</pub-id></mixed-citation></ref><ref id="CIT0144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cecchi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hulikova</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Pastorek</surname>
<given-names>J</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors</article-title>. <source>J Med Chem</source>
<year>2005</year>;<volume>48</volume>:<fpage>4834</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">16033263</pub-id></mixed-citation></ref><ref id="CIT0145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ahlskog</surname>
<given-names>JK</given-names></string-name>, <string-name><surname>Dumelin</surname>
<given-names>CE</given-names></string-name>, <string-name><surname>Tr&#x000fc;ssel</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2009</year>;<volume>19</volume>:<fpage>4851</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">19615903</pub-id></mixed-citation></ref><ref id="CIT0146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Buller</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Steiner</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Frey</surname>
<given-names>K</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Selection of carbonic anhydrase IX inhibitors from one million DNA-encoded compounds</article-title>. <source>ACS Chem Biol</source>
<year>2011</year>;<volume>6</volume>:<fpage>336</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">21186831</pub-id></mixed-citation></ref><ref id="CIT0147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lou</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>McDonald</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>Oloumi</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors</article-title>. <source>Cancer Res</source>
<year>2011</year>;<volume>71</volume>:<fpage>3364</fpage>&#x02013;<lpage>76</lpage>.<pub-id pub-id-type="pmid">21415165</pub-id></mixed-citation></ref><ref id="CIT0148"><label>148</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Krall</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Pretto</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Decurtins</surname>
<given-names>W</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A small-molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors</article-title>. <source>Angew Chem Int Ed Engl</source>
<year>2014</year>;<volume>53</volume>:<fpage>4231</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">24623670</pub-id></mixed-citation></ref><ref id="CIT0149"><label>149</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ebbesen</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Pettersen</surname>
<given-names>EO</given-names></string-name>, <string-name><surname>Gorr</surname>
<given-names>TA</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2009</year>;<volume>24</volume>: <fpage>1</fpage>&#x02013;<lpage>39</lpage>.</mixed-citation></ref><ref id="CIT0150"><label>150</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pettersen</surname>
<given-names>EO</given-names></string-name>, <string-name><surname>Ebbesen</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Gieling</surname>
<given-names>RG</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2015</year>;<volume>30</volume>:<fpage>689</fpage>&#x02013;<lpage>721</lpage>.<pub-id pub-id-type="pmid">25347767</pub-id></mixed-citation></ref><ref id="CIT0151"><label>151</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Alterio</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Di Fiore</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one</article-title>. <source>Med Res Rev</source>
<year>2018</year>;<volume>38</volume>:<fpage>1799</fpage>&#x02013;<lpage>836</lpage>.<pub-id pub-id-type="pmid">29635752</pub-id></mixed-citation></ref><ref id="CIT0152"><label>152</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McDonald</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>Winum</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Dedhar</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>Recent developments in targeting carbonic anhydrase IX for cancer therapeutics</article-title>. <source>Oncotarget</source>
<year>2012</year>;<volume>3</volume>:<fpage>84</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">22289741</pub-id></mixed-citation></ref><ref id="CIT0153"><label>153</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Angeli</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Nocentini</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment</article-title>. <source>Metabolites</source>
<year>2020</year>;<volume>10</volume>:<fpage>412</fpage>.</mixed-citation></ref><ref id="CIT0154"><label>154</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burianova</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Kalinin</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Krasavin</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>Radiotracers for positron emission tomography (PET) targeting tumour-associated carbonic anhydrase isoforms</article-title>. <source>Eur J Med Chem</source>
<year>2020</year>;<volume>2021</volume>:<fpage>113046</fpage>.</mixed-citation></ref><ref id="CIT0155"><label>155</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Andring</surname>
<given-names>JT</given-names></string-name>, <string-name><surname>Fouch</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Akocak</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structural basis of nanomolar inhibition of tumor-associated carbonic anhydrase IX: X-ray crystallographic and inhibition study of lipophilic inhibitors with acetazolamide backbone</article-title>. <source>J Med Chem</source>
<year>2020</year>;<volume>63</volume>:<fpage>13064</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">33085484</pub-id></mixed-citation></ref><ref id="CIT0156"><label>156</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alterio</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Hilvo</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Di Fiore</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2009</year>;<volume>106</volume>:<fpage>16233</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">19805286</pub-id></mixed-citation></ref><ref id="CIT0157"><label>157</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Whittington</surname>
<given-names>DA</given-names></string-name>, <string-name><surname>Waheed</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ulmasov</surname>
<given-names>B</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2001</year>;<volume>98</volume>:<fpage>9545</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">11493685</pub-id></mixed-citation></ref><ref id="CIT0158"><label>158</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Di Fiore</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Truppo</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Crystal structure of the C183S/C217S mutant of human CA VII in complex with acetazolamide</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2010</year>;<volume>20</volume>:<fpage>5023</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">20688517</pub-id></mixed-citation></ref><ref id="CIT0159"><label>159</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Di Fiore</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Monti</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Hilvo</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Crystal structure of human carbonic anhydrase XIII and its complex with the inhibitor acetazolamide</article-title>. <source>Proteins</source>
<year>2009</year>;<volume>74</volume>:<fpage>164</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">18618712</pub-id></mixed-citation></ref><ref id="CIT0160"><label>160</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alterio</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Pan</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Parkkila</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The structural comparison between membrane-associated human carbonic anhydrases provides insights into drug design of selective inhibitors</article-title>. <source>Biopolymers</source>
<year>2014</year>;<volume>101</volume>:<fpage>769</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">24374484</pub-id></mixed-citation></ref><ref id="CIT0161"><label>161</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pilka</surname>
<given-names>ES</given-names></string-name>, <string-name><surname>Kochan</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Oppermann</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Yue</surname>
<given-names>WW.</given-names></string-name></person-group>
<article-title>Crystal structure of the secretory isozyme of mammalian carbonic anhydrases CA VI: implications for biological assembly and inhibitor development</article-title>. <source>Biochem Biophys Res Commun</source>
<year>2012</year>;<volume>419</volume>:<fpage>485</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22366092</pub-id></mixed-citation></ref><ref id="CIT0162"><label>162</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Briganti</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Mangani</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Orioli</surname>
<given-names>P</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase activators: X-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine</article-title>. <source>Biochemistry</source>
<year>1997</year>;<volume>36</volume>:<fpage>10384</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">9265618</pub-id></mixed-citation></ref><ref id="CIT0163"><label>163</label><mixed-citation publication-type="journal" id="CIT0163-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase activators</article-title>. <source>Future Med Chem</source>
<year>2018</year>;<volume>10</volume>:<fpage>561</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">29478330</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0163-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Balaban</surname>
<given-names>AT.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase activators. Part 8. pKa&#x02013;activation relationship in a series of amino acid derivatives activators of isozyme II</article-title>. <source>Rev Roum Chim</source>
<year>1994</year>;<volume>39</volume>:<fpage>107</fpage>&#x02013;<lpage>13</lpage>. (c) <person-group person-group-type="author"><string-name><surname>Duda</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Tu</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Qian</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Structural and kinetic analysis of the chemical rescue of the proton transfer function of carbonic anhydrase II</article-title>. <source>Biochemistry</source>
<year>2001</year>;<volume>40</volume>:<fpage>1741</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="CIT0164"><label>164</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Temperini</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII, and XIV with l- and d-histidine and crystallographic analysis of their adducts with isoform II: engineering proton-transfer processes within the active site of an enzyme</article-title>. <source>Chemistry</source>
<year>2006</year>;<volume>12</volume>:<fpage>7057</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">16807956</pub-id></mixed-citation></ref><ref id="CIT0165"><label>165</label><mixed-citation publication-type="journal" id="CIT0165-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Temperini</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase activation and the drug design</article-title>. <source>Curr Pharm Des</source>
<year>2008</year>;<volume>14</volume>:<fpage>708</fpage>&#x02013;<lpage>15</lpage>.<pub-id pub-id-type="pmid">18336317</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0165-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Temperini</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Innocenti</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2007</year>;<volume>17</volume>:<fpage>628</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">17127057</pub-id></mixed-citation></ref><ref id="CIT0166"><label>166</label><mixed-citation publication-type="journal" id="CIT0166-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Temperini</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII, and XIV with L- and D-phenylalanine and crystallographic analysis of their adducts with isozyme II: stereospecific recognition within the active site of an enzyme and its consequences for the drug design</article-title>. <source>J Med Chem</source>
<year>2006</year>;<volume>49</volume>:<fpage>3019</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">16686544</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0166-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Temperini</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Innocenti</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase activators: kinetic and x-ray crystallographic study for the interaction of D- and L-tryptophan with the mammalian isoforms I-XIV</article-title>. <source>Bioorg Med Chem</source>
<year>2008</year>;<volume>16</volume>:<fpage>8373</fpage>&#x02013;<lpage>837</lpage>.<pub-id pub-id-type="pmid">18774300</pub-id></mixed-citation></ref><ref id="CIT0167"><label>167</label><mixed-citation publication-type="journal" id="CIT0167-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Dave</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Ilies</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Scozzafava</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>An inhibitor-like binding mode of a carbonic anhydrase activator within the active site of isoform II</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2011</year>;<volume>21</volume>:<fpage>2764</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">21036610</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0167-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Bhatt</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Mondal</surname>
<given-names>UK</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>crystal structure of carbonic anhydrase II in complex with an activating ligand: implications in neuronal function</article-title>. <source>Mol Neurobiol</source>
<year>2018</year>;<volume>55</volume>:<fpage>7431</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">29423818</pub-id></mixed-citation></ref><ref id="CIT0168"><label>168</label><mixed-citation publication-type="journal" id="CIT0168-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Innocenti</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Nishimori</surname>
<given-names>I</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase activators: activation of the human isoforms VII (cytosolic) and XIV (transmembrane) with amino acids and amines</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2007</year>;<volume>17</volume>:<fpage>4107</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">17540561</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0168-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Pastorekova</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Nishimori</surname>
<given-names>I</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase activators: activation of the human tumor-associated isozymes IX and XII with amino acids and amines</article-title>. <source>Bioorg Med Chem</source>
<year>2008</year>;<volume>16</volume>:<fpage>3530</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">18294854</pub-id></mixed-citation></ref><ref id="CIT0169"><label>169</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Nishimori</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Innocenti</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase activators: an activation study of the human mitochondrial isoforms VA and VB with amino acids and amines</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2007</year>;<volume>17</volume>:<fpage>1336</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">17174092</pub-id></mixed-citation></ref><ref id="CIT0170"><label>170</label><mixed-citation publication-type="journal">a). <person-group person-group-type="author"><string-name><surname>Saada</surname>
<given-names>MC</given-names></string-name>, <string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Montero</surname>
<given-names>JL</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase I and II activation with mono- and dihalogenated histamine derivatives</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2011</year>;<volume>21</volume>:<fpage>4884</fpage>&#x02013;<lpage>7</lpage>. (b) <person-group person-group-type="author"><string-name><surname>Saada</surname>
<given-names>MC</given-names></string-name>, <string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Montero</surname>
<given-names>JL</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Mono- and di-halogenated histamine, histidine and carnosine derivatives are potent carbonic anhydrase I, II, VII, XII and XIV activators</article-title>. <source>Bioorg Med Chem</source>
<year>2014</year>;<volume>22</volume>:<fpage>4752</fpage>&#x02013;<lpage>8</lpage>. (c) <person-group person-group-type="author"><string-name><surname>Vistoli</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Aldini</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Fumagalli</surname>
<given-names>L</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Activation effects of carnosine- and histidine-containing dipeptides on human carbonic anhydrases: a comprehensive study</article-title>. <source>Int J Mol Sci</source>
<year>2020</year>;<volume>21</volume>:<fpage>1761</fpage>.</mixed-citation></ref><ref id="CIT0171"><label>171</label><mixed-citation publication-type="journal" id="CIT0171-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Dinculescu</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Balaban</surname>
<given-names>AT.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase activators. Part 5. CA II activation by 2,4,6-trisubstituted pyridinium cations with 1-(&#x003c9;-aminoalkyl) side chains</article-title>. <source>Rev Roum Chim</source>
<year>1993</year>;<volume>38</volume>:<fpage>343</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation><mixed-citation publication-type="journal" id="CIT0171-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Draghici</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Akocak</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Ethylene bis-imidazoles are highly potent and selective activators for isozymes VA and VII of carbonic anhydrase, with a potential nootropic effect</article-title>. <source>Chem Commun (Camb)</source>
<year>2014</year>;<volume>50</volume>:<fpage>5980</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">24763985</pub-id></mixed-citation></ref><ref id="CIT0172"><label>172</label><mixed-citation publication-type="journal" id="CIT0172-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Akocak</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lolak</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Bua</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Activation of human &#x003b1;-carbonic anhydrase isoforms I, II, IV and VII with bis-histamine schiff bases and bis-spinaceamine substituted derivatives</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2019</year>;<volume>34</volume>:<fpage>1193</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">31237157</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0172-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Akocak</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lolak</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Bua</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>&#x003b1;-Carbonic anhydrases are strongly activated by spinaceamine derivatives</article-title>. <source>Bioorg Med Chem</source>
<year>2019</year>;<volume>27</volume>:<fpage>800</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">30683554</pub-id></mixed-citation></ref><ref id="CIT0173"><label>173</label><mixed-citation publication-type="journal">a). <person-group person-group-type="author"><string-name><surname>Chiaramonte</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Maach</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Biliotti</surname>
<given-names>C</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and carbonic anhydrase activating properties of a series of 2-amino-imidazolines structurally related to clonidine</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2020</year>;<volume>35</volume>:<fpage>1003</fpage>&#x02013;<lpage>10</lpage>. (b) <person-group person-group-type="author"><string-name><surname>Angeli</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Vaiano</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Mari</surname>
<given-names>F</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Psychoactive substances belonging to the amphetamine class potently activate brain carbonic anhydrase isoforms VA, VB, VII, and XII</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2017</year>;<volume>32</volume>:<fpage>1253</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="CIT0174"><label>174</label><mixed-citation publication-type="journal" id="CIT0174-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Zhang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Barboiu</surname>
<given-names>M.</given-names></string-name></person-group>
<article-title>Exponential activation of carbonic anhydrase by encapsulation in dynameric host matrices with chiral discrimination</article-title>. <source>Chemistry</source>
<year>2018</year>;<volume>24</volume>:<fpage>715</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">29119623</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0174-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Le Duc</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Licsandru</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrases activation with 3-amino-1H-1,2,4-triazole-1-carboxamides: discovery of subnanomolar isoform II activators</article-title>. <source>Bioorg Med Chem</source>
<year>2017</year>;<volume>25</volume>:<fpage>1681</fpage>&#x02013;<lpage>6</lpage>. (c) <person-group person-group-type="author"><string-name><surname>Licsandru</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Tanc</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kocsis</surname>
<given-names>I</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A class of carbonic anhydrase I - selective activators</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2017</year>;<volume>32</volume>:<fpage>37</fpage>&#x02013;<lpage>46</lpage>. (d) <person-group person-group-type="author"><string-name><surname>Zhang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Legrand</surname>
<given-names>YM</given-names></string-name>, <string-name><surname>Petit</surname>
<given-names>E</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Dynamic encapsulation and activation of carbonic anhydrase in multivalent dynameric host matrices</article-title>. <source>Chem Commun (Camb)</source>
<year>2016</year>;<volume>52</volume>:<fpage>4053</fpage>&#x02013;<lpage>5</lpage>. (e) <person-group person-group-type="author"><string-name><surname>Abdelrahim</surname>
<given-names>MY</given-names></string-name>, <string-name><surname>Tanc</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Winum</surname>
<given-names>JY</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Dominant behaviours in the expression of human carbonic anhydrase hCA I activity</article-title>. <source>Chem Commun (Camb)</source>
<year>2014</year>;<volume>50</volume>:<fpage>8043</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="CIT0175"><label>175</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Canto de Souza</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Provensi</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase activation enhances object recognition memory in mice through phosphorylation of the extracellular signal-regulated kinase in the cortex and the hippocampus</article-title>. <source>Neuropharmacology</source>
<year>2017</year>;<volume>118</volume>:<fpage>148</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">28286213</pub-id></mixed-citation></ref><ref id="CIT0176"><label>176</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Blandina</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Provensi</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Passsani</surname>
<given-names>MB</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase modulation of emotional memory. Implications for the treatment of cognitive disorders</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2020</year>;<volume>35</volume>:<fpage>1206</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">32401069</pub-id></mixed-citation></ref><ref id="CIT0177"><label>177</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schmidt</surname>
<given-names>SD</given-names></string-name>, <string-name><surname>Costa</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Rani</surname>
<given-names>B</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The role of carbonic anhydrases in extinction of contextual fear memory</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2020</year>;<volume>117</volume>:<fpage>16000</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">32571910</pub-id></mixed-citation></ref><ref id="CIT0178"><label>178</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jonsson</surname>
<given-names>BH</given-names></string-name>, <string-name><surname>Liljas</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>Perspectives on the classical enzyme carbonic anhydrase and the search for inhibitors</article-title>. <source>Biophys J</source>
<year>2020</year>;<volume>119</volume>:<fpage>1275</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">32910900</pub-id></mixed-citation></ref><ref id="CIT0179"><label>179</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Angeli</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Nocentini</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Response to perspectives on the classical enzyme carbonic anhydrase and the search for inhibitors</article-title>. <source>Biophys J</source>
<year>2021</year>;<volume>120</volume>:<fpage>178</fpage>&#x02013;<lpage>81</lpage>.<pub-id pub-id-type="pmid">33296668</pub-id></mixed-citation></ref><ref id="CIT0180"><label>180</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Experimental carbonic anhydrase inhibitors for the treatment of hypoxic tumors</article-title>. <source>J Exp Pharmacol</source>
<year>2020</year>;<volume>12</volume>:<fpage>603</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">33364855</pub-id></mixed-citation></ref><ref id="CIT0181"><label>181</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jonsson</surname>
<given-names>BH</given-names></string-name>, <string-name><surname>Liljas</surname>
<given-names>A.</given-names></string-name></person-group>
<article-title>Comments to the editor due to the response by the supuran group to our article</article-title>. <source>Biophys J</source>
<year>2021</year>;<volume>120</volume>:<fpage>182</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="pmid">33308476</pub-id></mixed-citation></ref><ref id="CIT0182"><label>182</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maryanoff</surname>
<given-names>BE</given-names></string-name>, <string-name><surname>Nortey</surname>
<given-names>SO</given-names></string-name>, <string-name><surname>Gardocki</surname>
<given-names>JF</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate and related compounds</article-title>. <source>J Med Chem</source>
<year>1987</year>;<volume>30</volume>:<fpage>880</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">3572976</pub-id></mixed-citation></ref><ref id="CIT0183"><label>183</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dodgson</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Shank</surname>
<given-names>RP</given-names></string-name>, <string-name><surname>Maryanoff</surname>
<given-names>BE.</given-names></string-name></person-group>
<article-title>Topiramate as an inhibitor of carbonic anhydrase isoenzymes</article-title>. <source>Epilepsia</source>
<year>2000</year>;<volume>41</volume>:<fpage>35</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">10768298</pub-id></mixed-citation></ref><ref id="CIT0184"><label>184</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Klinger</surname>
<given-names>AL</given-names></string-name>, <string-name><surname>McComsey</surname>
<given-names>DF</given-names></string-name>, <string-name><surname>Smith-Swintosky</surname>
<given-names>V</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements</article-title>. <source>J Med Chem</source>
<year>2006</year>;<volume>49</volume>:<fpage>3496</fpage>&#x02013;<lpage>500</lpage>.<pub-id pub-id-type="pmid">16759092</pub-id></mixed-citation></ref><ref id="CIT0185"><label>185</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shank</surname>
<given-names>RP</given-names></string-name>, <string-name><surname>Smith-Swintosky</surname>
<given-names>VL</given-names></string-name>, <string-name><surname>Maryanoff</surname>
<given-names>BE.</given-names></string-name></person-group>
<article-title>Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2008</year>;<volume>23</volume>:<fpage>271</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">18343915</pub-id></mixed-citation></ref><ref id="CIT0186"><label>186</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Casini</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Antel</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Abbate</surname>
<given-names>F</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2003</year>;<volume>13</volume>:<fpage>841</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">12617904</pub-id></mixed-citation></ref><ref id="CIT0187"><label>187</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nguyen</surname>
<given-names>GTH</given-names></string-name>, <string-name><surname>Tran</surname>
<given-names>TN</given-names></string-name>, <string-name><surname>Podgorski</surname>
<given-names>MN</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Nanoscale ion emitters in native mass spectrometry for measuring ligand-protein binding affinities</article-title>. <source>ACS Cent Sci</source>
<year>2019</year>;<volume>5</volume>:<fpage>308</fpage>&#x02013;<lpage>18</lpage>.<pub-id pub-id-type="pmid">30834319</pub-id></mixed-citation></ref><ref id="CIT0188"><label>188</label><mixed-citation publication-type="journal" id="CIT0188-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Nguyen</surname>
<given-names>GTH</given-names></string-name>, <string-name><surname>Nocentini</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Angeli</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Perfluoroalkyl substances of significant environmental concern can strongly inhibit human carbonic anhydrase isozymes</article-title>. <source>Anal Chem</source>
<year>2020</year>;<volume>92</volume>:<fpage>4614</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">32096628</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0188-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Nguyen</surname>
<given-names>GTH</given-names></string-name>, <string-name><surname>Leung</surname>
<given-names>WY</given-names></string-name>, <string-name><surname>Tran</surname>
<given-names>TN</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Mechanism for the binding of netropsin to hairpin DNA revealed using nanoscale ion emitters in native mass spectrometry</article-title>. <source>Anal Chem</source>
<year>2020</year>;<volume>92</volume>:<fpage>1130</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">31778608</pub-id></mixed-citation></ref><ref id="CIT0189"><label>189</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matulis</surname>
<given-names>D.</given-names></string-name></person-group>
<article-title>Structural details of the enzymatic catalysis of carbonic anhydrase II via a mutation of valine to isoleucine</article-title>. <source>IUCrJ</source>
<year>2020</year>;<volume>7</volume>:<fpage>953</fpage>&#x02013;<lpage>4</lpage>.</mixed-citation></ref><ref id="CIT0190"><label>190</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matulis</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Kranz</surname>
<given-names>JK</given-names></string-name>, <string-name><surname>Salemme</surname>
<given-names>FR</given-names></string-name>, <string-name><surname>Todd</surname>
<given-names>MJ.</given-names></string-name></person-group>
<article-title>Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor</article-title>. <source>Biochemistry</source>
<year>2005</year>;<volume>44</volume>:<fpage>5258</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">15794662</pub-id></mixed-citation></ref><ref id="CIT0191"><label>191</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Linkuvien&#x00117;</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Krainer</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>WY</given-names></string-name>, <string-name><surname>Matulis</surname>
<given-names>D.</given-names></string-name></person-group>
<article-title>Isothermal titration calorimetry for drug design: precision of the enthalpy and binding constant measurements and comparison of the instruments</article-title>. <source>Anal Biochem</source>
<year>2016</year>;<volume>515</volume>:<fpage>61</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">27717855</pub-id></mixed-citation></ref><ref id="CIT0192"><label>192</label><mixed-citation publication-type="journal" id="CIT0192-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Ruusuvuori</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Kaila</surname>
<given-names>K</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors: inhibition of the cytosolic human isozyme VII with anions</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2006</year>;<volume>16</volume>:<fpage>3139</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">16621537</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0192-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Franchi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Gallori</surname>
<given-names>E</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors. inhibition of cytosolic isozymes I and II and transmembrane, cancer-associated isozyme IX with anions</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2003</year>;<volume>18</volume>:<fpage>403</fpage>&#x02013;<lpage>6</lpage>. (c) <person-group person-group-type="author"><string-name><surname>Innocenti</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Vullo</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Pastorek</surname>
<given-names>J</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors. Inhibition of transmembrane isozymes XII (cancer-associated) and XIV with anions</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2007</year>;<volume>17</volume>:<fpage>1532</fpage>&#x02013;<lpage>7</lpage>. (d) <person-group person-group-type="author"><string-name><surname>Innocenti</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lehtonen</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Parkkila</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2004</year>;<volume>14</volume>:<fpage>5435</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="CIT0193"><label>193</label><mixed-citation publication-type="journal" id="CIT0193-gen-2">(a) <person-group person-group-type="author"><string-name><surname>S&#x0016b;d&#x0017e;ius</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Baranauskien&#x00117;</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Golovenko</surname>
<given-names>D</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>4-[N-(substituted 4-pyrimidinyl)amino]benzenesulfonamides as inhibitors of carbonic anhydrase isozymes I, II, VII, and XIII</article-title>. <source>Bioorg Med Chem</source>
<year>2010</year>;<volume>18</volume>:<fpage>7413</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">20889345</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0193-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>&#x0010c;apkauskait&#x00117;</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Zubrien&#x00117;</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Baranauskien&#x00117;</surname>
<given-names>L</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design of [(2-pyrimidinylthio)acetyl]benzenesulfonamides as inhibitors of human carbonic anhydrases</article-title>. <source>Eur J Med Chem</source>
<year>2012</year>;<volume>51</volume>:<fpage>259</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">22440859</pub-id></mixed-citation></ref><ref id="CIT0194"><label>194</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zubrien&#x00117;</surname>
<given-names>A</given-names></string-name>, <string-name><surname>&#x0010c;apkauskait&#x00117;</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Gylyt&#x00117;</surname>
<given-names>J</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Benzenesulfonamides with benzimidazole moieties as inhibitors of carbonic anhydrases I, II, VII, XII and XIII</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2014</year>;<volume>29</volume>:<fpage>124</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">23356363</pub-id></mixed-citation></ref><ref id="CIT0195"><label>195</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dudutien&#x00117;</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Matulien&#x00117;</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Smirnov</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Discovery and characterization of novel selective inhibitors of carbonic anhydrase IX</article-title>. <source>J Med Chem</source>
<year>2014</year>;<volume>57</volume>:<fpage>9435</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">25358084</pub-id></mixed-citation></ref><ref id="CIT0196"><label>196</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dudutien&#x00117;</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Zubrien&#x00117;</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Smirnov</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Functionalization of fluorinated benzenesulfonamides and their inhibitory properties toward carbonic anhydrases</article-title>. <source>ChemMedChem</source>
<year>2015</year>;<volume>10</volume>:<fpage>662</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">25758852</pub-id></mixed-citation></ref><ref id="CIT0197"><label>197</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zak&#x00161;auskas</surname>
<given-names>A</given-names></string-name>, <string-name><surname>&#x0010c;apkauskait&#x00117;</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Jezep&#x0010d;ikas</surname>
<given-names>L</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Design of two-tail compounds with rotationally fixed benzenesulfonamide ring as inhibitors of carbonic anhydrases</article-title>. <source>Eur J Med Chem</source>
<year>2018</year>;<volume>156</volume>:<fpage>61</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">30006175</pub-id></mixed-citation></ref><ref id="CIT0198"><label>198</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zak&#x00161;auskas</surname>
<given-names>A</given-names></string-name>, <string-name><surname>&#x0010c;apkauskait&#x00117;</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Jezep&#x0010d;ikas</surname>
<given-names>L</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Halogenated and di-substituted benzenesulfonamides as selective inhibitors of carbonic anhydrase isoforms</article-title>. <source>Eur J Med Chem</source>
<year>2020</year>;<volume>185</volume>:<fpage>111825</fpage>.<pub-id pub-id-type="pmid">31740053</pub-id></mixed-citation></ref><ref id="CIT0199"><label>199</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khalifah</surname>
<given-names>RG.</given-names></string-name></person-group>
<article-title>The carbon dioxide hydration activity of carbonic anhydrase</article-title>. <source>J Bio. Chem</source>
<year>1971</year>;<volume>246</volume>:<fpage>2561</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">4994926</pub-id></mixed-citation></ref><ref id="CIT0200"><label>200</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Paketuryt&#x00117;</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Zubrien&#x00117;</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ladbury</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Matulis</surname>
<given-names>D.</given-names></string-name></person-group>
<article-title>Intrinsic thermodynamics of protein-ligand binding by isothermal titration calorimetry as aid to drug design</article-title>. <source>Methods Mol Biol</source>. <year>2019</year>;<volume>1964</volume>:<fpage>61</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">30929235</pub-id></mixed-citation></ref><ref id="CIT0201"><label>201</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ki&#x00161;onait&#x00117;</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zubrien&#x00117;</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Capkauskait&#x00117;</surname>
<given-names>E</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Intrinsic thermodynamics and structure correlation of benzenesulfonamides with a pyrimidine moiety binding to carbonic anhydrases I, II, VII, XII, and XIII</article-title>. <source>PLoS One</source>
<year>2014</year>;<volume>9</volume>:<fpage>e114106</fpage>.<pub-id pub-id-type="pmid">25493428</pub-id></mixed-citation></ref><ref id="CIT0202"><label>202</label><mixed-citation publication-type="journal" id="CIT0202-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Khalifah</surname>
<given-names>RG</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Parr</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Rowe</surname>
<given-names>ES.</given-names></string-name></person-group>
<article-title>Thermodynamics of binding of the <sub>CO2</sub>-competitive inhibitor imidazole and related compounds to human carbonic anhydrase I: an isothermal titration calorimetry approach to studying weak binding by displacement with strong inhibitors</article-title>. <source>Biochemistry</source>
<year>1993</year>;<volume>32</volume>:<fpage>3058</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">8457566</pub-id></mixed-citation><mixed-citation publication-type="journal" id="CIT0202-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>An</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Tu</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Duda</surname>
<given-names>D</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Chemical rescue in catalysis by human carbonic anhydrases II and III</article-title>. <source>Biochemistry</source>
<year>2002</year>;<volume>41</volume>:<fpage>3235</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">11863462</pub-id></mixed-citation></ref><ref id="CIT0203"><label>203</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gaspari</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Rechlin</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Heine</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Kinetic and structural insights into the mechanism of binding of sulfonamides to human carbonic anhydrase by computational and experimental studies</article-title>. <source>J Med Chem</source>
<year>2016</year>;<volume>59</volume>:<fpage>4245</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">26700575</pub-id></mixed-citation></ref><ref id="CIT0204"><label>204</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Simone</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Alterio</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors</article-title>. <source>Expert Opin Drug Discov</source>
<year>2013</year>;<volume>8</volume>:<fpage>793</fpage>&#x02013;<lpage>810</lpage>.<pub-id pub-id-type="pmid">23627619</pub-id></mixed-citation></ref><ref id="CIT0205"><label>205</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gl&#x000f6;ckner</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ngo</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Sager</surname>
<given-names>CP</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Conformational changes in alkyl chains determine the thermodynamic and kinetic binding profiles of carbonic anhydrase inhibitors</article-title>. <source>ACS Chem Biol</source>
<year>2020</year>;<volume>15</volume>:<fpage>675</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">32027480</pub-id></mixed-citation></ref><ref id="CIT0206"><label>206</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gl&#x000f6;ckner</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ngo</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Wagner</surname>
<given-names>B</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The influence of varying fluorination patterns on the thermodynamics and kinetics of benzenesulfonamide binding to human carbonic anhydrase II</article-title>. <source>Biomolecules</source>
<year>2020</year>;<volume>10</volume>:<fpage>509</fpage>.</mixed-citation></ref><ref id="CIT0207"><label>207</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Snyder</surname>
<given-names>PW</given-names></string-name>, <string-name><surname>Mecinovic</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Moustakas</surname>
<given-names>DT</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Mechanism of the hydrophobic effect in the biomolecular recognition of arylsulfonamides by carbonic anhydrase</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2011</year>;<volume>108</volume>:<fpage>17889</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">22011572</pub-id></mixed-citation></ref><ref id="CIT0208"><label>208</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fox</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Kang</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Sastry</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Water-restructuring mutations can reverse the thermodynamic signature of ligand binding to human carbonic anhydrase</article-title>. <source>Angew Chem Int Ed Engl</source>
<year>2017</year>;<volume>56</volume>:<fpage>3833</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">28252841</pub-id></mixed-citation></ref><ref id="CIT0209"><label>209</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Breiten</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Lockett</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>Sherman</surname>
<given-names>W</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Water networks contribute to enthalpy/entropy compensation in protein-ligand binding</article-title>. <source>J Am Chem Soc</source>
<year>2013</year>;<volume>135</volume>:<fpage>15579</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">24044696</pub-id></mixed-citation></ref><ref id="CIT0210"><label>210</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fox</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Kang</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Sherman</surname>
<given-names>W</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Interactions between Hofmeister anions and the binding pocket of a protein</article-title>. <source>J Am Chem Soc</source>
<year>2015</year>;<volume>137</volume>:<fpage>3859</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">25738615</pub-id></mixed-citation></ref><ref id="CIT0211"><label>211</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Talibov</surname>
<given-names>VO</given-names></string-name>, <string-name><surname>Linkuvien&#x00117;</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Matulis</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Danielson</surname>
<given-names>UH.</given-names></string-name></person-group>
<article-title>Kinetically selective inhibitors of human carbonic anhydrase isozymes I, II, VII, IX, XII, and XIII</article-title>. <source>J Med Chem</source>
<year>2016</year>;<volume>59</volume>:<fpage>2083</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">26805033</pub-id></mixed-citation></ref><ref id="CIT0212"><label>212</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maren</surname>
<given-names>TH.</given-names></string-name></person-group>
<article-title>Direct measurements of the rate constants of sulfonamides with carbonic anhydrase</article-title>. <source>Mol Pharmacol</source>
<year>1992</year>;<volume>41</volume>:<fpage>419</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="pmid">1538718</pub-id></mixed-citation></ref><ref id="CIT0213"><label>213</label><mixed-citation publication-type="journal" id="CIT0213-gen-2">(a) <person-group person-group-type="author"><string-name><surname>Maren</surname>
<given-names>TH</given-names></string-name>, <string-name><surname>Clare</surname>
<given-names>BW</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT.</given-names></string-name></person-group>
<article-title>Structure-activity studies of sulfonamide carbonic anhydrase inhibitors</article-title>. <source>Roum Chem Quart Rev</source>
<year>1994</year>;<volume>2</volume>:<fpage>259</fpage>&#x02013;<lpage>82</lpage>.</mixed-citation><mixed-citation publication-type="journal" id="CIT0213-gen-3"> (b) <person-group person-group-type="author"><string-name><surname>Maren</surname>
<given-names>TH</given-names></string-name>, <string-name><surname>Conroy</surname>
<given-names>CW.</given-names></string-name></person-group>
<article-title>A new class of carbonic anhydrase inhibitor</article-title>. <source>J Biol Chem</source>
<year>1993</year>;<volume>268</volume>:<fpage>26233</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">8253744</pub-id></mixed-citation></ref><ref id="CIT0214"><label>214</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>K&#x000f6;hler</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Hillebrecht</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Schulze Wischeler</surname>
<given-names>J</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste</article-title>. <source>Angew Chem Int Ed Engl</source>
<year>2007</year>;<volume>46</volume>:<fpage>7697</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">17705204</pub-id></mixed-citation></ref><ref id="CIT0215"><label>215</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McDonald</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>Chia</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Bedard</surname>
<given-names>PL</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors</article-title>. <source>Am J Clin Oncol</source>
<year>2020</year>;<volume>43</volume>:<fpage>484</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">32251122</pub-id></mixed-citation></ref><ref id="CIT0216"><label>216</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lock</surname>
<given-names>FE</given-names></string-name>, <string-name><surname>McDonald</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>Lou</surname>
<given-names>Y</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche</article-title>. <source>Oncogene</source>
<year>2013</year>;<volume>32</volume>:<fpage>5210</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">23208505</pub-id></mixed-citation></ref><ref id="CIT0217"><label>217</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kreuzer</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Banerjee</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Birts</surname>
<given-names>CN</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Glycolysis, via NADH-dependent dimerisation of CtBPs, regulates hypoxia-induced expression of CAIX and stem-like breast cancer cell survival</article-title>. <source>FEBS Lett</source>
<year>2020</year>;<volume>594</volume>:<fpage>2988</fpage>&#x02013;<lpage>3001</lpage>.<pub-id pub-id-type="pmid">32618367</pub-id></mixed-citation></ref><ref id="CIT0218"><label>218</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gibadulinova</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bullova</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Strnad</surname>
<given-names>H</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>CAIX-mediated control of LIN28/let-7 axis contributes to metabolic adaptation of breast cancer cells to hypoxia</article-title>. <source>Int J Mol Sci</source>
<year>2020</year>;<volume>21</volume>:<fpage>4299</fpage>.</mixed-citation></ref><ref id="CIT0219"><label>219</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Swayampakula</surname>
<given-names>M</given-names></string-name>, <string-name><surname>McDonald</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>Vallejo</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion</article-title>. <source>Oncogene</source>
<year>2017</year>;<volume>36</volume>:<fpage>6244</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">28692057</pub-id></mixed-citation></ref><ref id="CIT0220"><label>220</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname>
<given-names>SH</given-names></string-name>, <string-name><surname>Griffiths</surname>
<given-names>JR.</given-names></string-name></person-group>
<article-title>How and why are cancers acidic? Carbonic anhydrase IX and the homeostatic control of tumour extracellular pH</article-title>. <source>Cancers (Basel)</source>
<year>2020</year>;<volume>12</volume>:<fpage>1616</fpage>.</mixed-citation></ref><ref id="CIT0221"><label>221</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ciccone</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Filippelli</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Angeli</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Pharmacological inhibition of CA-IX impairs tumor cell proliferation, migration and invasiveness</article-title>. <source>Int J Mol Sci</source>
<year>2020</year>;<volume>21</volume>:<fpage>2983</fpage>.</mixed-citation></ref><ref id="CIT0222"><label>222</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pastorekova</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Gillies</surname>
<given-names>RJ.</given-names></string-name></person-group>
<article-title>The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond</article-title>. <source>Cancer Metastasis Rev</source>
<year>2019</year>;<volume>38</volume>:<fpage>65</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">31076951</pub-id></mixed-citation></ref><ref id="CIT0223"><label>223</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname>
<given-names>SH</given-names></string-name>, <string-name><surname>McIntyre</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Honess</surname>
<given-names>D</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase IX is a pH-stat that sets an acidic tumour extracellular pH in&#x000a0;vivo</article-title>. <source>Br J Cancer</source>
<year>2018</year>;<volume>119</volume>:<fpage>622</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">30206370</pub-id></mixed-citation></ref><ref id="CIT0224"><label>224</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McDonald</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>Chafe</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>Brown</surname>
<given-names>WS</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Regulation of pH by carbonic anhydrase 9 mediates survival of pancreatic cancer cells with activated KRAS in response to hypoxia</article-title>. <source>Gastroenterology</source>
<year>2019</year>;<volume>157</volume>:<fpage>823</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="pmid">31078621</pub-id></mixed-citation></ref><ref id="CIT0225"><label>225</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Persi</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Duran-Frigola</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Damaghi</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Systems analysis of intracellular pH vulnerabilities for cancer therapy</article-title>. <source>Nat Commun</source>
<year>2018</year>;<volume>9</volume>:<fpage>2997</fpage>.<pub-id pub-id-type="pmid">30065243</pub-id></mixed-citation></ref><ref id="CIT0226"><label>226</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boyd</surname>
<given-names>NH</given-names></string-name>, <string-name><surname>Walker</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Fried</surname>
<given-names>J</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Addition of carbonic anhydrase 9 inhibitor SLC-0111 to temozolomide treatment delays glioblastoma growth in&#x000a0;vivo</article-title>. <source>JCI Insight</source>
<year>2017</year>;<volume>2</volume>:<fpage>92928</fpage>.<pub-id pub-id-type="pmid">29263302</pub-id></mixed-citation></ref><ref id="CIT0227"><label>227</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Iessi</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Logozzi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Mizzoni</surname>
<given-names>D</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Rethinking the combination of proton exchanger inhibitors in cancer therapy</article-title>. <source>Metabolites</source>
<year>2017</year>;<volume>8</volume>:<fpage>2</fpage>.</mixed-citation></ref><ref id="CIT0228"><label>228</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McDonald</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>Swayampakula</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Dedhar</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>Coordinated regulation of metabolic transporters and migration/invasion by carbonic anhydrase IX</article-title><source>. Metabolites</source>
<year>2018</year>;<volume>8</volume>:<fpage>20</fpage>.</mixed-citation></ref><ref id="CIT0229"><label>229</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chafe</surname>
<given-names>SC</given-names></string-name>, <string-name><surname>McDonald</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>Saberi</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Targeting hypoxia-induced carbonic anhydrase IX enhances immune-checkpoint blockade locally and systemically</article-title>. <source>Cancer Immunol Res</source>
<year>2019</year>;<volume>7</volume>:<fpage>1064</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">31088846</pub-id></mixed-citation></ref><ref id="CIT0230"><label>230</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Damgaci</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ibrahim-Hashim</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Enriquez-Navas</surname>
<given-names>PM</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Hypoxia and acidosis: immune suppressors and therapeutic targets</article-title>. <source>Immunology</source>
<year>2018</year>;<volume>154</volume>:<fpage>354</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">29485185</pub-id></mixed-citation></ref><ref id="CIT0231"><label>231</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kuchuk</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Tuccitto</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Citterio</surname>
<given-names>D</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>pH regulators to target the tumor immune microenvironment in human hepatocellular carcinoma</article-title>. <source>Oncoimmunology</source>
<year>2018</year>;<volume>7</volume>:<fpage>e1445452</fpage>.<pub-id pub-id-type="pmid">29900055</pub-id></mixed-citation></ref><ref id="CIT0232"><label>232</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ward</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Meehan</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Gray</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase IX (CAIX), cancer, and radiation responsiveness</article-title>. <source>Metabolites</source>
<year>2018</year>;<volume>8</volume>:<fpage>13</fpage>.</mixed-citation></ref><ref id="CIT0233"><label>233</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Doyen</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Parks</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Marci&#x000e9;</surname>
<given-names>S</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Knock-down of hypoxia-induced carbonic anhydrases IX and XII radiosensitizes tumor cells by increasing intracellular acidosis</article-title>. <source>Front Oncol</source>
<year>2012</year>;<volume>2</volume>:<fpage>199</fpage>.<pub-id pub-id-type="pmid">23316475</pub-id></mixed-citation></ref><ref id="CIT0234"><label>234</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Serbian</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Schwarzenberger</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Loesche</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Ureidobenzenesulfonamides as efficient inhibitors of carbonic anhydrase II</article-title>. <source>Bioorg Chem</source>
<year>2019</year>;<volume>91</volume>:<fpage>103123</fpage>.<pub-id pub-id-type="pmid">31336306</pub-id></mixed-citation></ref><ref id="CIT0235"><label>235</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vanchanagiri</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Emmerich</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Bruschke</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Synthesis and biological investigation of new carbonic anhydrase IX (CAIX) inhibitors</article-title>. <source>Chem Biol Interact</source>
<year>2018</year>;<volume>284</volume>:<fpage>12</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">29454615</pub-id></mixed-citation></ref><ref id="CIT0236"><label>236</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Federici</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Lugini</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Marino</surname>
<given-names>ML</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2016</year>;<volume>31</volume>:<fpage>119</fpage>&#x02013;<lpage>25</lpage>.</mixed-citation></ref><ref id="CIT0237"><label>237</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Andreucci</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Peppicelli</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Carta</surname>
<given-names>F</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis</article-title>. <source>J Mol Med (Berl)</source>
<year>2017</year>;<volume>95</volume>:<fpage>1341</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">28929255</pub-id></mixed-citation></ref><ref id="CIT0238"><label>238</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bryant</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Gieling</surname>
<given-names>RG</given-names></string-name>, <string-name><surname>Meredith</surname>
<given-names>SL</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer</article-title>. <source>Int J Cancer</source>
<year>2018</year>;<volume>142</volume>:<fpage>191</fpage>&#x02013;<lpage>201</lpage>.<pub-id pub-id-type="pmid">28905987</pub-id></mixed-citation></ref><ref id="CIT0239"><label>239</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Logsdon</surname>
<given-names>DP</given-names></string-name>, <string-name><surname>Grimard</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Luo</surname>
<given-names>M</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Regulation of HIF1&#x003b1; under hypoxia by APE1/Ref-1 impacts CA9 expression: dual targeting in patient-derived 3D pancreatic cancer models</article-title>. <source>Mol Cancer Ther</source>
<year>2016</year>;<volume>15</volume>:<fpage>2722</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">27535970</pub-id></mixed-citation></ref><ref id="CIT0240"><label>240</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Peppicelli</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Andreucci</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Ruzzolini</surname>
<given-names>J</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>The Carbonic Anhydrase IX inhibitor SLC-0111 as emerging agent against the mesenchymal stem cell-derived pro-survival effects on melanoma cells</article-title>. <source>J Enzyme Inhib Med Chem</source>
<year>2020</year>;<volume>35</volume>:<fpage>1185</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">32396749</pub-id></mixed-citation></ref><ref id="CIT0241"><label>241</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Genah</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Angeli</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Supuran</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Morbidelli</surname>
<given-names>L.</given-names></string-name></person-group>
<article-title>Effect of carbonic anhydrase IX inhibitors on human endothelial cell survival</article-title>. <source>Pharmacol Res</source>
<year>2020</year>;<volume>159</volume>:<fpage>104964</fpage>.<pub-id pub-id-type="pmid">32485281</pub-id></mixed-citation></ref><ref id="CIT0242"><label>242</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Riemann</surname>
<given-names>A</given-names></string-name>, <string-name><surname>G&#x000fc;ttler</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Haupt</surname>
<given-names>V</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Inhibition of carbonic anhydrase IX by ureidosulfonamide inhibitor U104 reduces prostate cancer cell growth, but does not modulate daunorubicin or cisplatin cytotoxicity</article-title>. <source>Oncol Res</source>
<year>2018</year>;<volume>26</volume>:<fpage>191</fpage>&#x02013;<lpage>200</lpage>.<pub-id pub-id-type="pmid">28631600</pub-id></mixed-citation></ref><ref id="CIT0243"><label>243</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>G&#x000fc;ttler</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Theuerkorn</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Riemann</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Cellular and radiobiological effects of carbonic anhydrase IX in human breast cancer cells</article-title>. <source>Oncol Rep</source>
<year>2019</year>;<volume>41</volume>:<fpage>2585</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">30720123</pub-id></mixed-citation></ref><ref id="CIT0244"><label>244</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Alexeyev</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kozhukhar</surname>
<given-names>N</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrase IX is a critical determinant of pulmonary microvascular endothelial cell pH regulation and angiogenesis during acidosis</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>
<year>2018</year>;<volume>315</volume>:<fpage>L41</fpage>&#x02013;<lpage>L51</lpage>.<pub-id pub-id-type="pmid">29631360</pub-id></mixed-citation></ref><ref id="CIT0245"><label>245</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Onanyan</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Garrison</surname>
<given-names>I</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Extrinsic acidosis suppresses glycolysis and migration while increasing network formation in pulmonary microvascular endothelial cells</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>
<year>2019</year>;<volume>317</volume>:<fpage>L188</fpage>&#x02013;<lpage>L201</lpage>.<pub-id pub-id-type="pmid">31042076</pub-id></mixed-citation></ref><ref id="CIT0246"><label>246</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bernardino</surname>
<given-names>RL</given-names></string-name>, <string-name><surname>Dias</surname>
<given-names>TR</given-names></string-name>, <string-name><surname>Moreira</surname>
<given-names>BP</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Carbonic anhydrases are involved in mitochondrial biogenesis and control the production of lactate by human Sertoli cells</article-title>. <source>Febs J</source>
<year>2019</year>;<volume>286</volume>:<fpage>1393</fpage>&#x02013;<lpage>406</lpage>.<pub-id pub-id-type="pmid">30724485</pub-id></mixed-citation></ref><ref id="CIT0247"><label>247</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Petrenko</surname>
<given-names>M</given-names></string-name>, <string-name><surname>G&#x000fc;ttler</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Funtan</surname>
<given-names>A</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Combined 3-O-acetylbetulin treatment and carbonic anhydrase IX inhibition results in additive effects on human breast cancer cells</article-title>. <source>Chem Biol Interact</source>
<year>2021</year>;<volume>333</volume>:<fpage>109326</fpage>.<pub-id pub-id-type="pmid">33245928</pub-id></mixed-citation></ref><ref id="CIT0248"><label>248</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Venkateswaran</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Dedhar</surname>
<given-names>S.</given-names></string-name></person-group>
<article-title>Interplay of carbonic anhydrase IX with amino acid and acid/base transporters in the hypoxic tumor microenvironment</article-title>. <source>Front Cell Dev Biol</source>
<year>2020</year>;<volume>8</volume>:<fpage>602668</fpage>.<pub-id pub-id-type="pmid">33240897</pub-id></mixed-citation></ref><ref id="CIT0249"><label>249</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brown</surname>
<given-names>WS</given-names></string-name>, <string-name><surname>McDonald</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>Nemirovsky</surname>
<given-names>O</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Overcoming adaptive resistance to KRAS and MEK inhibitors by co-targeting mTORC1/2 complexes in pancreatic cancer</article-title>. <source>Cell Rep Med</source>
<year>2020</year>;<volume>1</volume>:<fpage>100131</fpage>.<pub-id pub-id-type="pmid">33294856</pub-id></mixed-citation></ref></ref-list></back></article>